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ABSTRACT
THE LIVED EXPERIENCE: PULMONARY ARTERIAL HYPERTENSION 
AND INTRAVENOUS PROSTAGLANDIN THERAPY
By
Phyllis D. Boone
A descriptive phenomenological study was proposed to obtain a subjective 
description of the experience of living with intravenous prostaglandin treatment for 
pulmonary arterial hypertension. It was intended to determine what kinds of elements are 
common to the experience with study participants, to develop an aggregate structure of 
the experience from the individual descriptions of it, and add to what is now known about 
this phenomenon. It was anticipated that the stories told by the participants could help to 
determine how nurses can assist future patients to live optimally within the confines of a 
palliative treatment for this incurable illness.
Unfortunately, no participants responded to recruitment efforts by the researcher. 
However, the current state of nursing science about the experience of having pulmonary 
arterial hypertension was synthesized, and the utility of phenomenological exploration for 
nursing practice was discussed. Finally, the barriers to recruitment for researchers 
following the Health Insurance Portability and Accountability Act Privacy Rule were 
examined and approaches to overcome these barriers were determined.
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CHAPTER 1 
INTRODUCTION
Pulmonary arterial hypertension (PAH) group I, as defined by the World Health 
Organization (WHO) in 2003 (Simonneau, Galie, Rubin, Langleben, Seeger, & 
Domenighetti et al., 2004), is a progressive, life-threatening and incurable disease. The 
idiopathic and familial variants of PAH in group 1 (Appendix A) are uncommon, but 
affect 50,000 to 100,000 people in the United States. Of these, women are diagnosed at 2 
to 3 times the rate of men (Simonneau, et al.). The patient with idiopathic PAH is 
typically a young woman of childbearing age (Traiger, 2007). The remaining members of 
this group are of all races and ages. Their disease can be inherited, a result of cormective 
tissue diseases, human immunodeficiency virus, and congenital heart disease. It can also 
result from the use of anorexigens, and methamphetamine and cocaine abuse (Rubin & 
Hopkins, 2007).
The pathological manifestations seen in the pulmonary arterioles of patients with 
WHO classification Group 1 PAH include medial hypertrophy, intimai proliferation, 
concentric laminar fibrosis and plexiform and thrombotic lesions (Rich, 2000; Widlitz, 
McDevitt, Ward & Krichman, 2007). This arteriolar remodeling causes hemodynamic 
changes. In a healthy adult, the normal mean pulmonary artery pressure (mPAP) ranges 
from 10 to 17 mmHg and pulmonary vascular resistance (PVR) ranges from 60 to 100 
dynes/sec/cm5 (Swearingen & Hicks-Keen, 2001). For the adult with PAH, the mPAP,
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measured during right heart catheterization (RHC) is greater than 25 mmHg at rest and 
greater than 30 mmHg with exercise. The PVR increases to greater than 120 
dynes/sec/cm5 (Rubin & Hopkins, 2007). These sustained increases in mPAP and PVR 
lead to right heart failure and death within 3 to 5 years from diagnosis if  there is no 
pharmacologic intervention (Eells, 2004; Rubin & Hopkins, 2007; Sitbon, Humbert, 
Nunes, Parent, Garcia, Hervé, et al., 2002; Traiger, 2007). The hemodynamic changes 
affect day-to-day functioning of these patients, who experience progressively worsening 
cognition (White et al., 2006), shortness of breath, fatigue, liver congestion, peripheral 
edema and death (McPhee & Papadakis, 2008).
The New York Heart Association (NYHA)AVHO functional classification tool for 
PAH (Appendix B) is used to assess and classify the functional status of this patient 
population. This assessment tool is used on initial consultation and at all subsequent visits 
to the health-care provider (Rich, as cited in Traiger, 2007). It helps to clarify and classify 
the diagnosis of PAH as well as to assess treatment efficacy (Traiger, 2007).
Patients with severe PAH who have reached NYHA/WHO functional Class III or 
Class IV and remain in those classifications despite conventional treatments with oral 
vasodilators are considered for intravenous (IV) prostacyclin treatment (Depta & 
Krasuski, 2008; Roncesvalles, Lee, Camamo & Priestley, 2008). While the prostacyclins 
epoprostenol and treprostinil have significantly prolonged the lives of these patients 
(Barst, et al., 1996; McPhee & Papadakis, 2008; Sitbon, et al., 2002), those taking these 
drugs may suffer numerous side effects. The side effects include jaw spasm, headache, 
flushing, rash, nausea and diarrhea. Over time, they might experience side effects that 
include musculoskeletal pain, a blotchy-red rash, impotence, thrombocytopenia, and
ascites. Finally, if patients receive doses that are too high for an extended period, high- 
output cardiac failure can result (Traiger, 2007). Furthermore, epoprostenol has an 
elimination half-life of less than 6 minutes (Roncesvalles et al., 2008). This means that if 
epoprostenol is stopped abruptly for any reason, the patient will experience sudden 
increasing symptoms including rebound pulmonary hypertension, cardiovascular 
collapse, and death (Barst, et al., 1996; Roncesvalles et al., 2008; Traiger, 2007). The 
newer IV drug treprostinil, with an elimination half-life of 2-4 hours was developed to 
minimize the rapid decline associated with abrupt discontinuation of epoprostenol. 
Treprostinil is recommended as an alternative treatment for patients in NYHA/WHO 
functional Class IV (Roncesvalles et al., 2008).
In addition to the side effects listed above, patients needing IV prostacyclin must 
also contend with maintaining an implanted catheter, an infusion pump, continuous drug 
administration, storage and availability, infusion maintenance and emergency 
contingency plans. Given the drug side effects and the demands of treatment, the decision 
for treatment with either drug is made with the patient, family and healthcare providers 
based on the severity of the patient’s disease, the support available at home, lifestyle 
considerations and patient preference (Traiger, 2007). Patients needing IV treatment must 
be motivated, educated and well supported throughout their experienee with this 
treatment.
Background
Since 1995 much research has been done to evaluate the physiological impact of 
IV prostaglandin therapy on patients with PAH. These remarkable medicines, especially 
epoprostenol (Flolan®) (Barst, et al., 1996; Sitbon, et al., 2002) and its analog drug
treprostinil (Remodulin®) have shown an ability to improve functional capacity and 
survival in these patients. They are prescribed either as a bridge to lung transplantation or 
as palliative treatment for this incurable illness (Simonneau, et al., 2004). The drugs 
dilate the pulmonic and systemic vasculature and inhibit platelet aggregation (Depta & 
Krasuski, 2008; Eells, 2004; Flattery, Pinson, Savage & Salyer, 2005; McPhee & 
Papadakis, 2008; Roncesvalles et al., 2008; Traiger, 2007). They are now a main-stay in 
the treatment of functional Class III and Class IV PAH. But to date little research has 
been completed to determine how the complex and precise drug administration regimen, 
the monitoring requirements, and the demands of managing side effects when using these 
drugs impact the physical, emotional, and social well-being of these patients.
Nursing has always held a caring attitude with respect to others and their health 
and illness concerns. Trusting nurses on this account, patients have historically told 
nurses what is relevant or meaningful to them during times of illness and its treatment.
As nurses listened to their patients, they recognized that the experiences of patients share 
some similarities. Nurses then realized that this knowledge can be used to assist patients 
to live optimally within the limitations imposed by an illness and its treatments (King & 
Hinds, 2003; Rich, 2000; Watson, 2008). By obtaining a subjective description of the 
experience of living with IV prostaglandin treatment for PAH and determining the 
structure of the description with study participants, nurses will better understand the 
patients’ experiences and will develop interventions that both anticipate and support their 
needs.
Available Literature 
A literature search of the Cumulative Index of Nursing and Allied Health
Literature (CINAHL) database using the keywords pulmonary hypertension, drug
therapy, and nursing care, returned 47 results. A second search of the same database
using the keywords pulmonary hypertension, prostaglandins, and nursing care reduced
returns to six results. A third search adding the keywords quality of life returned two
more documents. Several studies were concerned with developing, using, and verifying
quantitative instruments to assess health-related quality of life (HrQOL) in patients with
PAH (Cenedese et al., 2006; Chen, Darren, Taichman & Doyle, 2008; McKenna,
Doughty, Meads, Do ward & Pepke-Zaba, 2006; Shafazand, Goldstein, Doyle, Hlatky &
Gould, 2004; Taichman, et al., 2005). Traiger (2007) wrote an article that focused on
managing IV and inhaled therapies for PAH, and addressed nursing strategies for helping
patients manage the side effects of their prescribed medications.
Within the search results was one qualitative study (Flattery et al., 2005)
investigating the lived experiences of patients with PAH arising from varied etiologies
and receiving diverse types of approved therapies. Emerging from this study was a
theme about managing uncertainty in illness—common to patients with chronic health
conditions (Hummel, 2009; Mishel, 1988). The second theme, related to the first, was
about coping with uncertainty in order to be able to move ahead with living.
Significance of the Study 
The scarcity of literature regarding the phenomenon of interest spoke to the need
for further research to enhance what is known about the issues and coping strategies
experienced by patients living with IV prostaglandin treatments. This qualitative study
sample of patients would be small, but the research was designed to be specific to the 
population. This research proposed to add to what is now known about the lived 
experiences of adult Group I patients with PAH who are receiving continuous IV 
prostaglandin treatment. It was anticipated that the stories these patients told could help 
to determine how nurses can assist them to live optimally within the confines of a 
palliative treatment for this incurable illness.
Study Objectives and the Research Question 
The objective of this study was to listen to the stories the participants would tell 
and to take in what comprises their experience. From the individual stories, common 
elements were to be dissected to determine what the general, essential structure of the 
phenomenon looks like. Developing this aggregate structure would allow nurses to 
generalize the experience of the study participants to similar, future situations.
To explore the participants’ subjective experiences while receiving IV 
prostaglandin treatment for PAH in their private home setting, a single open-ended 
research question was developed to encourage their reflection:
Can you tell me about what it is like for you to live with IV prostaglandin 
treatment for your pulmonary hypertension? Please share as many of your 
thoughts, experiences and feelings as you can recall.
My anticipated work as a researcher was to present the collective experience of 
the selected participants “in... enough detail and... depth [so] that those who read the 
study can connect to that experience, learn how it is constituted, and deepen their 
understanding of the issues it reflects” (Seidman, 2006, p. 51).
CHAPTER 2
THE RESEARCH TRADITION OF PHENOMENOLOGY
The manner in which a phenomenon presents itself to the consciousness of the 
researcher is important for determining the strategies needed for studying it (Giorgi, 
2009). As a nurse, I ask how should I learn about the suffering of another, and what can 
be done about such suffering? Because the purpose of this study was to determine the 
patients’ experiences during IV treatment for PAH, an approach influenced by 
phenomenology was thought to be a useful philosophy and methodology to use for this 
research.
Philosophical Background 
Phenomenology is both a philosophy and a method (Giorgi, 2009). The word 
phenomenon comes from the Greek language and means to “appear” or to “show itself.” 
The philosophy of phenomenology appeared in Germany before the First World War, 
challenging the dominant viewpoints about the origin and nature of truth at that time 
(Dowling, 2007). Edmund Husserl is considered to be the father of this philosophical 
movement. In a rudimentary way, phenomenology can be depicted as “the sustained 
attempt to describe experiences... without metaphysical and theoretical speculations” 
(Sawicki, 2006, Introduction, T| I). Husserl regarded experience as the fundamental 
source of knowledge, and is associated with developing the principle of intentionaliiy. 
Dowling (2007) states that “Intentionality is the principle that every mental act is related 
to some object and implies that all perceptions have meaning.... [it]... refers to the
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internal experience of being conscious of something” (p. 132). The goal of 
phenomenology for Husserl was to study things as they appear to consciousness in order 
to arrive at an essential understanding of human consciousness (Dowling, 2007).
Husserl believed human consciousness exists in a separate sphere from the natural 
sphere of the physical existence of man. So, in order to study the things as they appear to 
human consciousness and understand such consciousness, he thought it necessary to 
come to a third sphere of absolute or transcendental consciousness. Husserl posited that 
this absolute consciousness exists outside of the spheres of natural human existence and 
human consciousness (Sawicki, 2006). Husserl called the roadmap needed for arriving at 
this essential understanding of consciousness via the transcendental consciousness, 
phenomenological reduction. Phenomenological reduction is a methodological attempt 
by the phenomenologist
to meet the phenomenon as free and as unprejudiced as possible [from within the third 
sphere] in order that the phenomenon present itself [in] as free and as unprejudiced [a] 
way as possible so that it can be precisely described and understood (Dowling, 2007, p. 
132).
Husserl’s contribution to phenomenological reduction was later modified by his 
student, Martin Heidegger, who defined phenomenology not as philosophy, but rather as 
method (Heidegger, 1962/1927). Unlike his mentor, Heidegger did not separate man’s 
natural existence from his consciousness. He brought them together as inseparable in his 
work. Being and Time. His aim for phenomenology was not to provide a philosophically 
detached, descriptive analysis of consciousness from the sphere of transcendental 
consciousness. Instead, he redefined phenomenology to be a method of analysis using
phenomenological reduction to bring to light understanding of the human being whose 
“behavior occurs in the context of relationships to things, people, events and situations” 
(Morse & Richards, 2002, p. 45). For Heidegger, Husserl’s phenomenological reduction 
became a means for exploring human being.
Later, Merleau-Ponty (1962) in the Phenomenology of Perception would deepen 
the concept that natural human existence (body) is inseparable from consciousness 
(mind). From Husserl’s principle of intentionality, Merleau-Ponty developed the concept 
“that a person’s description [of an experience] is a perception [which is] a form of 
interpretation” (Morse & Richards, 2002, p. 46). Along with Heidegger, he held open the 
door for psychology and the human sciences to analyze being from a phenomenological 
perspective. Amedeo Giorgi (1970, 1985, 1997, and 2009) would soon after develop a 
scientific phenomenological method in order to help inform the experience of being from 
the perspective of scientific psychology (Giorgi & Giorgi, 2003) specifically, and more 
generally, for the human sciences which include nursing.
The Role of Phenomenology
For a great part of my own nursing career, I have worked at the bedsides of 
chronieally and critically ill patients undergoing various medical treatments for acute 
exacerbations of underlying illnesses. These periods of illness have been life-threatening 
to the individual involved. Confronted with these situations, I often would wonder if I 
were doing enough to affect the present and future well-being of patients in my care.
How are my patients experiencing the care I am providing? How can I provide care that 
matters to them in terms of living a good quality of life? Limited by the demands of
bedside nursing in a critical care ward, I was unable to explore more than the immediate 
generalities of each patient’s experiences.
As a result of my graduate studies, I became aware that phenomenological 
research methods could be used to search for answers to my questions. This is because 
phenomenology offers to us that “perceptions present us with evidence of the world—not 
as it is thought to be, but as it is lived... and that human existence is meaningful and of 
interest in the sense that we are always conscious of something” (Morse & Richards, 
2002, p. 45). In addition, phenomenological researchers have shown nurses that;
... it is possible to explicate [a] person’s experience to enhance an understanding. 
The responses... can provide the health practitioner with an added insight, a 
greater understanding of the everyday world of a person experiencing such an 
event... [That] can enamor the health professional’s empathy and substantiate and 
direct their style of care (Robertson-Malt, 1999; p. 292)
As a method, phenomenology is respectful of a person’s capacity for self- 
knowledge and his or her ability to communicate this (Robertson-Malt, 1999). It also 
recognizes that the human experience occurs within a context-what Heidegger 
(1962/1927) iQrvoQdi situated-ness. As an analytical method, phenomenology gives nurses 
a rigorous way to dissect the lived experience and its meaning from everyday language 
into the more explicit language of the human science of nursing. This happens without 
spoiling the way that these experiences present themselves to everyday life. The 
phenomenological method encourages the researcher to reflect on and identify factors 
that influence the everyday lives of the participants as well (Giorgi, 1985, 2009).
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By using a phenomenological approach to the research question, it is possible for 
the participants to talk about the experience of living with IV treatment for PAH in a non­
structured, open way during an interview. This approach asks that the researcher pay 
attention to the everyday language used to describe the experience just as it is given. The 
subsequent descriptive phenomenological analysis guides the researcher to determine the 
structure of the phenomenological description given to the experience by the participants. 
The task of the nurse researcher is to maintain the context of this lived experience for the 
participants and to share the findings with nurses and other health care providers so that 
future care for participants and for future patients in similar situations can be modified 
accordingly (Robertson-Malt, 1999).
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CHAPTER 3 
METHODS
In phenomenology, many scholars have developed a variety of inductive methods 
that have guided examinations into the underlying being of human experienee. Common 
to the methods is a philosophical premise that asks the researcher to ‘return to the things 
themselves’ which in turn directs and brings together the different methods of 
phenomenological analysis (Robertson-Malt, 1999). One such scholar, Amedeo Giorgi 
(2009), provides a method of phenomenological description that would be useful for this 
study. Giorgi’s (1985, 2009; Giorgi & Giorgi, 2003) method of descriptive 
phenomenological inquiry provides a framework upon which to expose and explore the 
key structure of a phenomenon.
Giorgi (1985, 2009; Giorgi & Giorgi, 2003) developed, described and published 
the steps of phenomenological analysis to meet the rigor of scientific research in the 
human sciences. His writings identify five basic steps that he believes all qualitative 
methods share. The methodological steps are outlined below:
1) Collecting verbal data which is transcribed verbatim
2) Reading the data
a) Read the entire text of the experience to get a sense of the whole
b) Reread the description
3) Breaking the data into some kind of parts
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a) Identify the transition units of the experience
b) Clarify and elaborate the meaning by relating constituents to each other and the 
whole
4) Organizing, expressing the data from a disciplinary perspective
a) Reflection on the constituents in the concrete language of the participant
b) Transform concrete language into the language or concepts of science
5) Synthesizing or summarizing the data for the purpose of communicating it to the 
scholarly community
The application of this method to this study will be discussed further in the data analysis 
section below.
Sampling
Effective research begins with choosing an appropriate population sample for the 
investigation. In order to gather the best description of the phenomenon of interest in a 
phenomenological study, “it is essential that all participants experience the phenomenon 
being studied” (Creswell, 1998, p. 118). In this study, it was planned that all participants 
chosen would be people who are living with IV prostaglandin treatment for PAH. This 
kind of sampling is called criterion sampling.
To participate in this study, participants would meet the criteria listed below:
1. Age of 18 years or older, fluent in the English language, capable of reflection 
and articulation, and with the time needed for an interview, and willing to 
participate in a private interview.
2. Participants must be classified with Class III or Class IV New York Heart 
Association/World Health Organization Functional Criteria for PAH. These
13
stages represent disease that has progressed to the point where the 
prostaglandin treatment will be needed.
3. Are medically stable-not currently hospitalized.
4. Must be receiving IV prostaglandin therapy for treatment of PAH.
Participant Recruitment and Consents
Participants in this study were to be selected from clients who are patients in a 
local PAH clinic operated by a regional health care system in the Midwestern section of 
the United States. Access to the clinic staff was given by the Senior Nurse Researcher at 
the health care system (K. J. YanderLaan, personal communication, July 30, 2009). 
Permission to utilize resources at the clinic was given by the nurse manager at the clinic 
pending approval of the study by the Human Research Review Committee (HRRC) at 
Grand Valley State University and by the Institutional Review Board (IRE) of Spectrum 
Health (A. Byme-Meyer, personal communication, September 18, 2009).
This study was conducted according to Department of Health and Human 
Services Title 45 Part 46 Protection of Human Subjects regulations and Institutional 
research policies and procedures. Subject to HRRC approval at Grand Valley State 
University and the IRB at Spectrum Health Hospitals, patient contact was to be made in 
accordance with the above regulatory statements. A letter granting permission to move 
forward with this research project utilizing resources at the Heart Failure, Transplant and 
Pulmonary Hypertension Clinic was obtained (Appendix C).
Clients receiving IV prostaglandin treatment were given an introductory letter 
identifying the study and its objectives (Appendix D), and a stamped, self-addressed 
envelope by the clinic staff. The number of letters distributed was determined by the
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number of patients in the practice meeting criteria. The PAH census for patients receiving 
prostaglandin treatment at the clinic averages 3 to 5 in any given month (A. Byme- 
Meyer, personal communication, November 19,2009).
To maintain confidentiality but yet help stimulate an adequate response from 
clients recruited for the study, two strategies were used. One strategy was to send a 
postcard reminder (Appendix E) to each of the patients who received a recmitment letter 
from the clinic staff. The reminder card was sent one to two weeks after the recruits 
received the introductory letter without regard to the actual individual responses to 
recruitment.
Second, to take advantage of the interest that a potential participant may have had 
in the study, without inadvertent disclosure of patient identities or diagnoses (protected 
health information), as the researcher I made myself available at the site of the clinic on 
several clinic days. I was to be in an area of the building secluded from the reception, 
waiting and examination areas where patients are seen (so the medical diagnosis of 
patients will not be possible to guess because of the equipment that must accompany 
them everywhere they travel). This placement would allow me to readily access the clinic 
in a timely manner to meet the patients who gave consent to have me discuss the study 
with them. I had no access to the identities of eligible participants until candidates 
interested in the study approached me at the clinic or provided written consent to release 
their names and contact information to me. Similarly, upon explaining the study and 
determining the interest of the patient in participating, I would not reveal to the clinic 
staff members whether consent to participate in the study was given. It was in light of the
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small patient census and time available for the completion of the research, that I was 
anticipating recruiting three to five participants for this study.
Following the receipt of returned letters from respondents confirming their desire 
to participate in this study, each participant was to be contacted by telephone or by e-mail 
using the information given in the response letter. After allowing an opportunity for the 
participant to ask pertinent questions, the participant would then be asked for the address 
of his or her home or place of residence, and an appointment would be made for the 
research interview. Upon their agreement to interview, each respondent was to be 
assigned a participant number which would be the only identifier used in the recording, 
the transcription and the final study report. Next, a second letter was to be sent to each 
participant. This letter (Appendix F) contained information regarding expectations during 
the interview as well as a copy of the informed consent and HIPAA Authorization for 
Release of Health Information for Research Purposes (Appendix G). In this letter the 
participant was asked to review this information before the interview appointment.
At the interview appointment the participant was to be provided an opportunity to 
have any questions or concerns about the study clarified (Appendix H). Then, he or she 
would be asked to sign the consent form and the HIPAA authorization form for release of 
health information for research purposes. The protected health information (PHI) 
requested for release included demographic data consisting of the participants’ name, 
date of birth, and insurance status. Social history was requested to determine marital 
status, living arrangements and religious practices. Health data requested incorporated the 
participants’ previous health history, the age at which PAH was diagnosed, and the 
etiology of the PAH. The name of the drug currently being used for treatment and the
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reason for choosing IV treatment were to be requested. Functional health status results as 
assessed using the NYHA/WHO modification (Appendix B) at the beginning of IV 
prostaglandin treatment and at the time of the interview was to be requested. The results 
of available tests used to diagnose PAH, including echocardiograms, right heart 
catheterization, histopathology results, electrocardiograms (EKGs), pulmonary function 
tests (PFTs), 6 minute walk tests (6MWT), results of pulse oximetry (Sp02) monitoring 
and arterial blood gasses (ABGs) were to be asked for as part of the consent. The results 
of tests used to monitor the progression of PAH including EKGs, 6 MWTs, Sp02 or 
ABG determinations were to be requested as well.
Once the consent for the release of the above information was obtained, the 
interview was to take place. As the researcher, I would seek permission for access to each 
participant’s medical records from the health care system. This would occur following 
approval to conduct this study from the health care system IRB. Only after consent had 
been given would the medical record have been accessed to obtain and record the 
permitted data.
The Phenomenological Reduction as Preparation for Collecting and Analyzing Data
In qualitative research, the phenomenological reduction “is the scientific process 
in which a researcher suspends or holds in abeyance... presuppositions, biases, 
assumptions, theories, or previous experiences [in order] to see and describe the 
phenomenon” (Gearing, 2004, p. 1430). Recognizing and acknowledging the existence of 
these elements is an important step to accomplish “before beginning the study and 
repeatedly throughout data collection and analysis” (Streubert-Speziale & Carpenter, 
2007, p.27). The purpose of the phenomenological reduction is to clarify beliefs about the
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phenomenon, to withhold judgments about what is being observed or heard as the data is 
disclosed, and to remain open to data as they are revealed. As such, the reduction 
preserves objectivity (Streubert-Speziale & Carpenter).
According to Giorgi (2008), achieving and maintaining phenomenological 
reduction during a study requires two activities:
(1) The researcher has to bracket [italics added] personal and past 
knowledge... not based on direct intuition, regardless of its source, so that full 
attention can be given to the instance of the phenomenon that is currently 
appearing to his or her consciousness; and (2) the researcher... does not make the 
claim that the object or event really exists in the way that it is appearing. It is seen 
to be a phenomenon (The interpretation of the phenomenological reduction,  ^2). 
Addressing the second element first, Moran (cited in Dowling, 2007) states that “this 
means that explanations about a phenomenon are not to be imposed before the 
phenomena have [first] been understood from within” (p. 132).
Bracketing is an attitudinal perspective invented by Husserl to make the 
descriptions required by phenomenology more rigorous. First a mathematician, Husserl 
conceptualized bracketing as in a mathematical equation. In such an equation bracketing 
is used to “[suspend] certain components by placing them outside the brackets... which 
then facilitates a focusing in on the phenomenon within the brackets” (Gearing, 2004, pp. 
1430-1431).
LeVasseur (2003) clarified the concept of bracketing by defining what requires 
suspension. She identified two kinds of conscious attitudes articulated by Husserl. One 
attitude is the philosophical attitude which is “a reflective and questioning perspective”
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(p. 417). The second is our everyday attitude toward the world which Husserl called the 
natural attitude. The natural attitude encompasses “the ordinary lack of curiosity with 
which most of life is lived” (p. 417). The natural attitude prevents us from experiencing 
repeated daily encounters as completely new at each occurrence, allowing us to routinely 
go about our daily lives. LeVasseur posited that phenomenological researchers should 
“regard bracketing as extending only to our natural attitude” (p. 417). Thus, bracketing 
becomes an interval,
... where momentarily we are dispossessed of our assumptions by an upstart 
curiosity, that new perception of the thing might occur.... [Where] the project of 
bracketing attempts to get beyond the ordinary assumptions of understanding and 
stay persistently curious about new phenomena.... [Providing an] opportunity for 
fresh experience and the possibility of new horizons of meaning (LeVasseur, pp. 
418-419).
However, the process of bracketing data about the phenomenon of interest from 
the influence of the researcher’s previous suppositions has proven problematic (Gearing, 
2004; Giorgi, 2008, 2009; LeVasseur, 2003). How does a researcher enter into this 
interval of persistent curiosity described by LeVasseur? Gearing offers some helpful 
guidance while navigating the process of bracketing for this study.
Gearing (2004) traces the development of the process of bracketing which 
parallels the evolution of phenomenological thought. Her typology reveals six kinds of 
processes. They range from Husserl’s ideal type and the Dutch (Utrecht) school’s 
descriptive bracketing, through the existential bracketing of Merleau-Ponty, to the more 
recent analytical, reflexive and pragmatic bracketing processes. The kind of bracketing
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process chosen by a researcher is dependent on the orientation standpoint of the 
researcher and the theoretical framework chosen for the research project.
The underlying structure of each bracketing process is the same regardless of the 
type of bracketing used by the researcher. The bracketing process has three distinct 
phases and each phase is comprised of specific elements (Gearing, 2004). The procedural 
phases and elements are shown as they occur within the context of descriptive bracketing 
(See Table 3).
Table 3: The Phases o f Bracketing: The Elements o f Each Phase and the Specific 
Components o f Descriptive Bracketing
Phase Element Component o f  Descriptive 
Bracketing
Abstract formulation Post positivism, interpretative
Orientation
Standpoint
Critical realism, relativism
Theoretical
Framework
Descriptive or Utrecht phenomenology 
quahtahve theories
Research Praxis
Foundational Focus Researcher sets aside suppositions; 
focuses in on immediate
Internal (Researcher) 
Supposition
Most held in abeyance
2 0
External
(Phenomenon)
Supposition
Most held in abeyance
Temporal Structure Begins and ends around specific 
phenomenon
Parenthesis Natural
(Boundaries)
composition
Reintegration/unbracketing and 
investment
Occurs after investigation of 
phenomenon; interpretation of data 
occurs after investigation.
Note. Table adapted from Gearing (2004).
The descriptive form of bracketing is appropriate for the proposed study because 
to date, little is known about this phenomenon. Descriptive phenomenology focuses on 
the immediate experience to determine the structure of a phenomenon through intuiting, 
analyzing, and describing, and is consistent with the descriptive methodology of Giorgi 
(1985, 2009; Giorgi & Giorgi, 2003).
The process of bracketing would begin before starting data collection. A self- 
reflective exercise was to be carried out to examine my personal influence in all aspects 
of this study. This is called reflexivity. Primeau (cited in Streubert-Speziale and Carpenter 
2007, p. 36) states, “reflexivity enhances the quality of research through its ability to
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extend our understanding of how our positions and interests as researchers affect all 
stages of the research process (p. 9)”. Streubert-Speziale and Carpenter add that “as 
researchers, it is our responsibility to reflect on our influence, critically analyze it, and 
use it to enhance our work, always being aware of the fact that no research is without its 
subjective aspects” (p. 36). I was to maintain ajournai throughout the data collection and 
analysis process to document my suppositions and my analysis of any preceding or 
ongoing influence on the data (Creswell, 1998). Journaling was to be used to support the 
bracketing process that maintains research objectivity.
Collecting Data; The Process of the Interview
The interview is the primary means of collecting data for a phenomenological 
study. The interviews are in-depth and involve a small number of individuals— usually as 
few as one or as many as ten (Creswell, 1998). From the interview, “what is sought is a 
concrete, detailed description of the subject’s experience and actions, as faithful as 
possible to what happen[s] as experienced by the subject” (Giorgi, 1997, Philosophical 
Method, 12).
After obtaining an informed, signed consent for research participation and HIPAA 
authorization for release of medical records from each subject, verbal data about the 
primary research question was to be collected from the participants. Data would be 
obtained during a private interview that was to be conducted in the home or current 
residence of the participant. The single, 45 to 60 minute unstructured, one-on-one 
interview was devised to allow the participant to express his or her viewpoint about the 
primary research question at length.
2 2
In addition to the primary research question, cue questions were developed within 
the framework of the primary research question. These cue questions included:
1. What was your life like before you needed this treatment?
2. Can you tell me about your life now—have there been changes?
3. Would you tell me how you feel about being on the IV medicine?
4. What is this experience like for you?
5. Is there anything else about having this treatment that you would like to 
share?
These cue questions were to be used during the interview as needed to stimulate further 
reflection about the participant’s experience with the phenomenon. Additional questions 
may have been developed during the interview in accordance with the range of the 
subject’s reflection, an interview guide (Appendix H), and my own clinical knowledge of 
the subject matter. The interviews were to be digitally recorded for later transcription to 
text (Seidman, 2006).
Potential Benefits to Participants or to Others
Participants in this study may or may not have experienced benefits as a result of their 
participation. Although it was not a goal of this research to enact a therapeutic 
relationship with the participants, some authors have noted that focused listening or 
attending is viewed as an element of positive nurse-patient relationships (Godkin, 2001; 
McCabe, 2004), and there is a body of research that suggests that the act of “telling 
stories” of stressful experiences may reduce the emotional and physical effects of the 
stress (Gale, Mitchell, Garand & Wesner, 2003; Pennebaker & Seagal, 1999; Sakalys, 
2003). As the planned research would employ a method that involved participants’ 
recounting of stories of their illnesses, it was possible that some might have experienced
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a reduction in anxiety or concern about their situation, even if  they demonstrated greater 
emotional upset while describing it. However, the greater benefit would be for future 
patients in that the information gained by nurses from this study may have helped us to 
better understand what life is like for patients while on intravenous medicine for PAH. 
The information may have helped nurses to develop new ways to care for patients who 
share a similar experience.
Anticipated Risks o f Harm or Discomfort to Participants and Protections against Risks
During the interview, participants may describe emergent concerns or the student 
researcher may note issues requiring professional attention. These issues may include, for 
example, recognition of changes in the individual’s ability to cope, distressing symptoms 
or side effects, or problems with administering the medication. Participants would have 
been provided with a contact number at the Heart Failure, Transplant and Pulmonary 
Hypertension Clinic (Appendix I). At that number, the participant would be connected to 
the appropriate professional able to attend to a specific problem. It is noteworthy that the 
clinic’s licensed social worker was a member of the student researcher’s thesis 
committee, and she could have been explicitly named as a resource for the participant.
For equipment problems, contact numbers were provided for medical equipment 
suppliers in the community, with suggestions of ways the problem could be described to 
the service representative to evoke a suitable and prompt response.
The physical effort required by the interview might have been tiring for the 
participant. The pace of the interview was to be directed by the participant, and the 
participant could stop the interview at any time he or she believed it would have been too 
hard to finish because of discomforts such as shortness of breath. The interview process
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may have brought up areas that caused emotional discomfort. Every effort would have 
been made to minimize such occasions, but the researcher was to stop the interview if it 
was determined that continuing would cause increasing discomfort. If necessary, the 
researcher may have requested that the interview be scheduled at another time. In cases 
where emotional responses of concern rose to the surface, actions described previously 
for encouraging consultation with the clinic personnel would have been pursued. As 
noted previously, however, by relating their stories, participants may have also 
experienced some relief from stress.
Data Analysis
Qualitative researchers are concerned with data quality. Does the narrative 
description obtained during the interview reflect the truth about the state of this particular 
human experience? Giorgi (2009) has developed a method to enhance the product of 
credibility, transferability, confirmability and dependability to equal the trustworthiness 
of data from a phenomenological study. These criteria from Lincoln and Guba (cited in 
Creswell, 1998; Polit & Beck, 2004) apply to both the assessment of the qualitative data 
and to the evaluation of interpretations and conclusions drawn from the data. I planned to 
use Giorgi’s (2009) method of descriptive phenomenological data analysis to form a 
description of the essential structure of living with the experience of taking IV 
prostaglandin treatment for PAH.
Polit and Beck (2004) state that... "Credibility [italics added] refers to confidence 
in the truth of the data and interpretations of them... .credibility involves carrying out the 
study in a way that enhances the believability of the findings, and... taking steps to 
demonstrate [italics in original] credibility to consumers” (p. 430). Researcher credibility
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begins with careful use of the phenomenological reduction in order to describe and 
interpret the data cleanly. In addition, my data and findings were to be discussed with 
members of my thesis committee who are experienced in the methods of 
phenomenological inquiry and with the phenomenon of interest (Polit & Beck).
When qualitative researchers talk about dependability, the researchers are 
referring to “the stability of the data over time and over conditions” (Polit & Beck, 2004, 
p. 434). One way to approach verification of dependability is to subject the acquired data 
and relevant supporting documents to an inquiry audit by an external reviewer (Polit & 
Beck). As stated previously, my data and findings were to be discussed with a member of 
my thesis committee who is experienced in phenomenological methodology throughout 
the process of data transcription and analysis.
Confirmability of data is defined by Polit and Beck (2004) as ... “refer[ing] to the 
objectivity or neutrality of the data, that is, the potential for congruence between two or 
more independent people about the data’s accuracy, relevance, or meaning” (p. 435). 
Confirmability is enhanced by using phenomenological reduction and by maintaining a 
reflective journal by the researcher. An audit trail consisting of “a systematic collection 
of materials and documentation that allows an independent auditor to come to 
conclusions about the data” (Polit & Beck, p. 435) will be available should an audit of my 
research be made. Interview recordings and transcripts, process notes, reflexive notes and 
data reconstruction products were to be retained as required by the Grand Valley State 
University HRRC (2007) procedure.
Finally, ""transferability [italics added] refers... to the generalizability of the data, 
that is, the extent to which the findings can be transferred to other settings or groups”
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(Polit & Beck, 2004, p. 435). In part, transferability reflects the sampling and study 
design. It is less a reflection of the soundness of the data. The burden on the researcher is 
to provide “a... thorough description of the research setting or context and of 
the...processes observed during the inquiry” (Polit & Beck, p. 436). Transferability 
requires that enough information about the phenomenon of interest be provided so that 
consumers may make judgments about contextual similarity (Creswell, 1998; Polit & 
Beck).
Reading the Data
Achieving transferability requires a well-organized description of the 
phenomenon of interest—in this case, the experience of having PAH and being treated 
with IV prostaglandins. Reading the text of each interview seems obvious. It is however, 
important to define what is involved in reading the text of the interviews during this first 
step of data analysis in order to lay the foundation for a well-organized description. Once 
transcribed from the recording, the descriptive text is read initially in the manner of an 
overview with no particular attitude (Giorgi, 1985, 2009; Giorgi & Giorgi, 2003). Then 
the text is read again. According to Wertz (1985);
The researcher attempts to put [herself] in the subject’s shoes and to live through 
the experience from the inside so that [she] is not a mere spectator but achieves a 
grasp of the meanings the subject has expressed precisely as intended by the 
subject (p. 164).
Establishing a meticulous baseline description is an important step that is necessary in 
qualitative research.
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Breaking the Data into Some Kinds o f Parts
Phenomenology is interested in meaning—the particular way in which an object 
is experienced (Giorgi, 2009). During the process of the re-reading of the data, the 
researcher begins to establish the meaning units in the data. Meaning units are defined 
initially as ... ”a purely descriptive term that signifies that a certain meaning, relevant for 
the study, and to be clarified further, is contained within the segregated unit” (Giorgi, 
1997, Philosophical Method, % 20) and then by Wertz (1985) as “a part of the description 
whose phrases require each other to stand as a distinguishable moment” (p. 165). 
Meaning units are formed within the attitude of the scientific phenomenological 
reduction. This early segregation of the interview data into meaning units is preparation 
for eventual analysis of the data. When done prudently, this step insures that all the data 
are carefully treated and accounted for (Giorgi, 2009; Giorgi & Giorgi, 2003).
Having established meaning units, the researcher decides what will or will not 
inform understanding of the phenomenon. Having an unspecified attitude is necessary 
here to maintain the phenomenological reduction. That is. .. ”in order to discover 
meanings in the data, [the researcher] needs an attitude open enough to let unexpected 
meanings emerge... [and by maintaining an unspecified attitude] one’s professional 
sensitivity and spontaneity function[s] so that relevant meanings can be intuited” (Giorgi, 
1997, Philosophical Method, f  21). In this phase, the challenge to the researeher is to 
distinguish reflexivity to the phenomenon in each meaning unit in any way possible 
(Wertz, 1985). If reflexivity to the investigated phenomenon is not found in a meaning 
unit of the interview text, it is removed. Remaining constituents that are related to each 
other will be brought together.
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The last step of this opening phase of data analysis involves the removal of 
redundant statements from the data. A re-description of the experience is then constructed 
from a first-person perspective in the participant’s own language. The result is an 
individual phenomenal description from each interview which will serve as a basis for 
further analysis (Wertz, 1985). Read by the participant, this construction would be “an 
obvious restatement of their own phenomenal experience with no analysis or 
interpretation” (Wertz, pp. 168-169). While still in this early phase, the nursing 
perspective in the individual phenomenal description will not be explicit. However the 
understanding, judgments about relevance and the organization of the elements of the 
phenomenal description will be drawn from the perspective of nursing as human caring, 
or caritas (Watson, 2008).
Organizing and Expressing the Data into the Disciplinary Language of Nursing
From a phenomenological viewpoint, the life-world [of the subject] is pre- 
theoretical and pre-scientific and not yet theoretical or scientific in itself. [But it] is the 
foundation... and so its [language] must be taken up, examined and re-described more 
rigorously from the perspective of a chosen discipline (Giorgi, 1997, Philosophical 
Method, H 24).
During this next step of analysis, the statements of the subjects will be 
transformed to the language of nursing. This is necessary because the statements of the 
subjects are in the language of everyday life. The language of nursing that will be used 
for analysis is not as broadly based as the language of everyday life (Giorgi, 1997) but 
does serve to narrow the focus of the data to nursing and to make the data more 
manageable. How then does the phenomenological researcher examine the raw data to
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discover, gain insight about and make sense of the data from the professional perspective 
while not losing contact with the lived situation of the subject?
This is where Giorgi’s (1985, 2009) method offree imaginative variation is first 
employed in order to help establish the essential intuitions along disciplinary lines. In 
Giorgi’s (2009) words, the practice of free imaginative variation is demonstrated:
An active imagination is helpful when trying to discover the essence of a 
phenomenon or attempting to clarify the meaningful structure of an experience. 
Free imaginative variation requires that one mentally remove an aspect of the 
phenomenon that is to be clarified in order to see whether the removal transforms 
what is presented in an essential way. If the given appears radically different 
because of the removal of a part, it is leaning toward being essential. If the given 
is still recognizable as the same after the removal of a part, it is most likely a 
contingent part... each of these decisions has to be critically evaluated by the 
researcher through further imaginative effort before a final assessment can be 
made (pp. 69-70).
In this way, the researcher contemplates the details of the description. Using free 
imaginative variation, the researcher determines what must be involved in the 
phenomenon, thus snaring essential determinations of the phenomena for each individual 
subject (Wertz, 1985).
The new phenomenal description now will be in the voice of the researcher but 
originating from contact with the subject. It is the expression of reflection on the text 
from within the context of the concept of nursing’s caring consciousness (Watson, 2008). 
This is essential for understanding and communicating another person’s perspective to
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nurses (Cara, n.d.). The aecuracy of this description was to be ensured by maintaining 
constant contact with the original phenomenal description for verification, modification 
or negation of any reflective understanding brought to the surface through free 
imaginative variation (Wertz, 1985).
An individual description of the phenomenon as it relates to nursing was to be 
developed exposing the structure of each individual case. To reveal the structure of a 
phenomenon means to identify “the constituents that are essential for the phenomenon to 
manifest itself in [a] particular way as well as [to] understand... how the constituents 
relate to each other” (Giorgi, 2009, p. 200). The structure was intended to show how 
everything essential to the individual in the experience of living with IV prostaglandin 
treatment comes from the participant’s description. The nursing narrative would bring 
light to the phenomenon from the nursing perspective as it maintains association with the 
participant’s own depiction.
Synthesizing or Summarizing the Data for the Purpose of Communicating to the 
Scholarly Community
Wertz (1985) draws our attention to the limitations of the individual structure.
The individual structure reflects “only an individual instance of the phenomenon”
(p. 188). Moving from each individual structure to a more general structure of a 
phenomenon requires “understanding [the] diverse individual cases as instances of 
something more general and articulating that generality of which there are particular 
instances” (p. 189). The process of shifting each individual structure of the phenomenon 
to a more generalized, aggregate structure that is transferable to other instances of the
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phenomenon is dependent on attitudes and operations similar to those already discussed 
(Wertz).
When looking again at the individual structures, the researcher was to assess those 
descriptions for meanings, themes and relations that are articulated and true of all cases. 
The researcher may find that an individual feature can pertain to many individuals, but 
not necessarily to all of the individuals in the study.” The researcher... determine[s] 
which features of the individual structure [represent] a general truth [about the 
phenomenon] and which [features] do not (p. 189). But none of these truths can be 
assumed (Wertz, 1985). Individual descriptions were to be tested for evidence of the 
general truth about a phenomenon in all of the descriptions. The descriptions were to be 
not only cross-checked, but reflection and free imaginative variation was to be employed. 
Application of the method of imaginative variation (Giorgi, 2009) at this juncture was 
hoped to give insight into what is generally essential to the phenomenon. This 
questioning act would establish what is necessary and not necessary to the phenomenon, 
defining what is needed to understand what is true of the phenomenon (Wertz).
Finally, the essential common elements were to be pulled together to describe the 
general structure of the experience of living while on IV prostaglandin treatment for 
PAH. Following completion of this very deliberate analysis, the researcher would have 
presented the essential structure of this phenomenon in language nurses understand and 
use in practice. Within the discussion section of the results of the study, thoughts about 
the meanings of the study findings for nursing practice were to be brought to light, and 
determining what questions remain to be answered for nursing would be discussed.
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CHAPTER 4 
RESULTS
The protocol for conducting this clinical research study was approved by the 
university’s HRRC and by the IRB at the hospital in August of 2010 (Appendix J). Upon 
approval, contact was made with the PAH clinic staff, a participant recruitment in-service 
was conducted by the researcher (Appendix K), and several recruitment packages were 
left with the nursing staff to distribute to clients receiving IV prostaglandin therapy as 
treatment for their pulmonary hypertension. The recruitment procedure was double- 
blinded to protect patient privacy.
To maintain clinic staff awareness of the proposed study, the staff was contacted 
regarding the study at one month and again at the sixth and eighth weeks of the 
recruitment period. Despite the distribution of recruitment packages to eligible 
participants by clinic staff members, no responses were returned to the researcher. At 
eight weeks approval for a modified recruitment protocol was sought from both the 
HRRC at the university and the IRB at the hospital. The revision allowed the researcher 
to be on site but secluded from patient reception and examination areas on the days that 
the pulmonary hypertension clinic would be conducted. The new arrangement would 
allow direct patient access to the researcher should the patient be curious about the 
opportunity to participate in this study. It was expected that the number of potential
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obstacles caused by the need to return a letter to the researcher would be reduced, 
facilitating participant recruitment.
This revision was approved by both committees by the last week in November 
(Appendix J). Unfortunately, despite these additional efforts, by the seventeenth week of 
the recruitment period no patient had responded to enrollment requests. Given the limited 
time frame for completion of the study and having exhausted the anticipated pool of 
recruits, a consultation was held with the thesis committee chairperson. It was determined 
that this study would be closed in late December 2010, and an examination of the 
experience of living with IV prostaglandin treatment would be conducted by examining 
themes found in the current body of literature and defining the related nursing 
implications.
Themes from the Literature 
This study proposed to obtain a subjective description of the experience of living 
with IV prostaglandin treatment for PAH. It was intended to determine what kinds of 
elements are common to the experiences of study participants and to develop an 
aggregate structure of the experience from their individual descriptions of it. It was hoped 
that the research findings would add to what is now known about this phenomenon. It 
was anticipated that the stories told by the participants could help to determine how 
nurses can help future patients to live optimally within the confines of a palliative 
treatment for this incurable illness.
To date, there are still few studies specific to the experiences of patients with 
PAH. This researcher was able to find only one qualitative study describing the 
experiences of patients living with PAH (Flattery et al., 2005). Other studies were found
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that described physical and emotional symptoms associated with the disease (Lowe, et 
al., 2004; Rubenfïre et al., 2009; Shafazand et al., 2004; Taichman, et al., 2005; White, 
Hopkins, Glissmeyer, Kitterman & Elliott, 2006; Wryobek, Lippo, McLaughlin, Riba & 
Rubenfïre, 2007) and problems affecting patient’s quality of life (Reubenfire et al., 2009; 
Wryobek et al., 2007).
Experiencing Physical and Emotional Symptoms
From the literature, there is a great deal of evidence supporting an elevated 
presence of anxiety, panic disorders, panic attacks and depression among patients who 
have PAH (Lowe, et al., 2004; Reubenfire et al., 2009; Shafazand et al., 2004;
Taichman, et al., 2005; White et al., 2006; Wryobek et al., 2007). Lôwe, et al. constructed 
a broadly based study using members from a European, non-profit, pulmonary 
hypertension organization to investigate whether anxiety disorders, depression or other 
mental disorders were actually more prevalent in this patient group. The study 
participants were located in Germany, Switzerland and Austria. The 164 participants 
were matched with 164 control patients with inflammatory rheumatic disease (IRD) and 
164 control primary care (PC) patients. The controls had chronic problems not causing 
dyspnea. All groups were well matched for age, sex, educational level and nationality. 
Notably, 6.5% of the PAH patients were on IV prostaglandin therapy, and work disability 
was 45% higher in the PAH group than in either the IRD or PC groups.
All study participants completed the Patient Health Questionnaire (PHQ), a self­
administered instrument used to diagnose mental disorders in non-psychiatric settings 
(Lowe, et al., 2004). Patients with pulmonary hypertension were assigned to one of the 
four NYHA functional classes predicated upon their report of dyspnea at various levels of
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physical activity (Lôwe, et al ). From the questionnaire, it was determined that the 
prevalence of participants with PAH who experienced panic attacks was 25%; 
experienced a panic disorder was 10.4%; and had a major depressive disorder was 15.9%. 
BRD and PC participants who experienced panic attacks was 12.2% and 14.0% 
respectively; experienced a panic disorder was 6% and 4% respectively; and a major 
depressive disorder was 18% and 17%, respectively.
The results showed that at least one third of patients with pulmonary hypertension 
suffer from panic disorder and a major depressive disorder, and there was a very high 
prevalence of panic attacks among patients with pulmonary hypertension. These findings 
by Lôwe, et al. (2004) were significant when compared to those of the groups not 
experiencing dyspnea. It appeared from the study findings that panic attacks and panic 
disorders were less likely a function of prostanoid therapy for PAH and more likely a 
function of the advancing stages of the disease; and, according to Lôwe, et al., as in other 
patients with medical diagnosis, only 24% identified as having a mental disorder reported 
being treated for it.
In the study by Lôwe, et al. (2004) the data collected was reported on a self- 
administered questionnaire. While using interviews to establish psychiatric diagnosis is 
considered the gold standard reference (Lôwe, et al.), the use of reliable, sensitive, 
specific and validated self-report instruments like the PHQ to ascertain the presence of 
psychiatric symptoms in the study participants should not diminish the quality of the 
findings from this research. There may have been sampling bias related to the fact that 
the sample group participants were members of a pulmonary hypertension organization.
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Strengths of the study included equivalent representation in the control groups of equally 
matched participants without respiratory disease.
In addition to emotional disruptions, persons with PAH demonstrated 
physiological disturbances beyond the effects of the disease on the pulmonary 
vasculature. Despite reports by patients of problems with memory and attention. White et 
al. (2006) found little information on the subject. So researchers determined to study the 
relationship between PAH and cognitive impairment in a well-defined PAH population.
Forty-six subjects, 38 (82.6%) of them female, with a mean age of 48.2 (± 11.8 
years) were enlisted in the study (White et al., 2006). The participants were evaluated to 
confirm the diagnosis of familial or idiopathic PAH by a board certified pulmonologist. 
The mean value of the time from diagnosis of PAH to testing for this study was 2.6 years. 
Twenty-eight participants were on IV prostacyclins and 30 were receiving supplemental 
oxygen. Each participant was subjected to extensive neuropsychological testing which 
was administered in person using a comprehensive battery of validated instruments. 
Among the tests used were the Beck Depression Inventory, the Beck Anxiety Inventory 
and the 36-item Medical Outcomes Short Form. Before and after testing, the oxygen 
saturation level and heart rate of each participant were evaluated to ensure that their 
oxygen levels were within normal limits during the tests.
White et al. (2006) found that there was a high incidence (58%) of cognitive 
sequelae associated with PAH. The impairment was found across an array of cognitive 
domains, including motor abilities, memory, mental processing speed, executive function 
and attention. Specifically, patients in the study struggled with activities requiring 
memory, executive function, attention, and rapid mental functioning. Of interest to this
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researcher was the report of one patient who wrestled with memory problems that caused 
her to make mistakes when mixing her medicine. “[She] would forget which steps she 
had completed [while preparing Flolan®]... .To prevent using incorrectly mixed 
medication, she discarded the medicine and started over. [The result was] wasted 
medication and increased drug costs” (White et al., 2006, Discussion, 1 2).
Within the findings of this study. White et al. (2006) found a 26% prevalence of 
moderate to severe depression and a 20% prevalence of moderate to severe anxiety 
among this cohort of study participants. In this study, the relationship between cognitive 
function, depression or anxiety and the kinds of medication therapy used among the 
participants was not examined. However, the prevalence of these disorders is no less 
noteworthy for patients receiving IV prostacyclin therapy, given that patients needing IV 
medications have severe disease and have endured the illness for a long time.
Shafazand et al. (2004) found that patients who were severely ill but on 
epoprostenol had better scores for emotional distress. It was postulated that this might 
have occurred in part because of drug effect, but was more likely a result of having a 
longer duration of disease at the time of the study. Patients on epoprostenol
... had more time to understand their disease, accept their functional limitations, 
develop coping strategies and build an adequate support system... .they have more 
interactions with physicians and nurses... and may be... selected because of their 
ability to cope with the challenges of such therapy ... .Nevertheless, compared 
with population norms, they continued to have substantial functional and 
emotional limitations...(pp. 1457-1458).
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The examined literature demonstrated that functional status for patients with PAH 
declined with the increasing severity of the disease, symptoms of the disease and with 
emotional responses (Lowe, et al., 2004; Rubenfire et al., 2009; Shafazand et al., 2004; 
Taichman, et al., 2005; White et al., 2006; Wryobek et al., 2007). Instruments used to 
measure the severity of illness among participants included the WHO Functional 
Classification (Appendix A), the NYHA Functional class (Appendix B), and the 6-minute 
walk test (6MWT). The Nottingham Health Profile, the Saint George’s Respiratory 
Questionnaire, and the Minnesota Living with Heart Failure Questionnaire were among 
instruments used to measure disease symptoms. Measures used to assess emotional 
responses included the Patient Health Questiormaire, the Hospital Anxiety and 
Depression Scale; and, in the study by Lowe, et al. (2004), the Beck Depression 
Inventory and the Beck Anxiety Inventory.
Living with Uncertainty
The research done by Flattery et al. (2005) identified that the over-arching theme 
of living with PAH is to experience a great deal of uncertainty. In this study, eight 
women and three men were interviewed using a semi-structured interview design. Six of 
the eleven participants were on a prostacyclin analog. The experiences of these six 
participants were not analyzed and segregated from the experiences of the other patients 
who were receiving other authorized treatments for PAH. The study participants 
described learning to cope with the uncertainties associated with their illness and moving 
on with their lives.
39
Coping, as described by the researcher, was characterized in several ways. It was 
associated with seeking information, with making memories, using humor, engaging in 
spirituality and with seeking support. Flattery et al. (2005) summarized the concept of 
moving on with life with these descriptors: “[Doing] what I have to do. . . . [Making] 
adjustment[s] to treatment.... [And] resuming life’s activities” (p. 102).
During the long period of diagnosis, several participants reported that they sought 
information using the internet (Flattery et al, 2005). One participant who did this 
reported that “the hardest thing was not knowing” (p. 101), but sometimes the knowing 
was difficult: “...it said the life expectancy was 3 to 5 years. It was a shock” (p. 101). 
Another woman coped by making memories through painting pictures for various family 
members “for them and for me” (p. 101). Others used humor as a coping strategy, and 
spirituality played a role as well. “... [If] you got a strong faith, you go with that. If you 
don’t. I’m not sure what you do” (p. 102). Several reported that they were involved in 
support groups that helped them to cope with having PAH.
It appeared that the participants on IV prostacyclins had to make many 
adjustments to life with treatment, as their comments were highlighted during this part of 
the analysis. On mixing epoprostenol: “It’s just a part of my life, it’s just what I do... like 
everything else... .You can make a huge thing out of anything, and I don’t think mixing 
Flolan® is a huge thing” (Flattery et al., 2005, p. 105). As they made adjustments, a 
participant noted that “it’s added years to my life... but it’s bittersweet in a way” (p. 102). 
Those adjustments were often difficult but eventually resolved to a new definition of 
what would become normal in their lives. Many reported that they were able to resume 
activities as a result of the physical improvement their treatment brought. One reported
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resuming gardening and fishing but “I can’t do it as long before I have to rest” (p. 102). 
One participant summed up the thoughts of many participants when he said, “I tell 
people, you have a pie every day and you have so many pieces of it and you have to 
figure out that once you use it up, it is gone” (p. 102).
Living with End-of-Life Concerns
Managing end-of-life issues poses a burden on patients and their care givers. 
Patients who have PAH die as a result of right heart failure or from sudden cardiac death, 
and, anecdotally, have not survived cardiopulmonary resuscitation (CPR). Hoeper, Galié, 
Murali, Olschewski, Rubenfire and Robbins et al. (2002) investigated the outcome of 
CPR in a group of PAH patients to validate its effectiveness. The study was retrospective, 
using multiple centers in both Europe and the United States. Between 1997 and 2000, 513 
patients had a circulatory arrest. Of those, 132 received CPR in a hospital environment, 
and the results were unsuccessful in 104 (79%) of the patients. An additional 13% died 
within 7 days. Eight survivors of more than 90 days and without neurological deficit had 
rapidly reversible identifiable causes of their circulatory arrests. The researchers 
concluded that “CPR for circulatory arrest in this patient population is rarely successful 
unless the cause of the cardiopulmonary decompensation can be corrected” (Abstract).
Wyrobeck et al. (2007) notes that an additional, unique problem for PAH patients 
nearing the end of life may be the denial of hospice care because of the expense of their 
IV prostacyclin treatment. Yet, if discontinued, death would occur within minutes to 
hours (Barst, et al., 1996; Roncesvalles et al., 2008; Traiger, 2007). Wyrobeck et al. 
likens “the decision to stop the IV prostacyclin [as] comparable to removing a conscious
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patient from a ventilator... so, without hospice care, the patient and family are left with 
few choices and limited support... [when most needed]” (p. 473).
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CHAPTERS
DISCUSSION
Practice Implications of Themes in the Literature
The results of the literature review show that there remains little in the literature
that determines what it is like to experience PAH. Moreover, there is a lack of studies that
separate human responses to the experience of treatment for PAH with continuous
intravenous medicines. It is not known whether the lived experience of patients on IV
prostaglandins is by nature different from the experiences of others with PAH receiving
oral and inhaled therapies. What is known is that as a group, patients with PAH suffer
high levels of major depressive disorders, anxiety disorders, panic disorders and panic
attacks. There is disease-related progressive decline in physical function, cognition and
memory, which may progressively and concurrently affect individual coping responses
(Lowe, et al., 2004; Rubenfire et al., 2009; Shafazand et al., 2004; Taichman, et a l, 2005;
White et al, 2006; Wryobek et al, 2007). It is known that PAH patients must marshal an
arsenal of coping strategies to contend with the uncertainties associated with their
diagnosis, the life sustaining medicines and equipment, and the effects of treatment.
Patients with PAH are vulnerable, and developing research protocols that will help nurses
to identify effective interventions for this patient population needs to be done.
Until such research is completed, some recommendations for nursing care of the
patient receiving IV prostaglandin treatment for PAH can be made, based on the findings
of the literature review and by understanding MisheTs (1990) reconceptualized theory of
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uncertainty in illness. Mishel found that uncertainty can be viewed in two ways; first, 
within a mechanistic paradigm where uncertainty is viewed “as an enemy that must be 
eliminated” (p. 261); and second, in the probabilistic paradigm where uncertainty is 
viewed as a naturally inherent part of human existence. In the probabilistic paradigm, life 
experience cannot be determined with certainty. Within this paradigm, however, nurses 
can partner with chronically ill patients to use uncertainty as a springboard for expanding 
possibilities and growth. According to Mishel (1990), within this partnership nurses may 
help patients explore new ways to complete desired activities, consider different ways to 
adjust to the changing nature of the illness or promote the idea that many factors can 
influence treatment response in order to “facilitate the patient’s evaluation of uncertainty 
and promote a probabilistic view of life [with chronic illness]” (p. 261). Through this 
process, nurses can help and support patients living with PAH to cope with the 
uncertainties of their disease and its treatment in healthy and creative ways.
The finding by White et al. (2006) that 58% of the patients with PAH in their 
study experienced cognitive impairments across all of the cognitive domains is 
significant. Living with PAH requires immense physical, emotional and social 
adjustments (Traiger, 2007). Cognitive impairments add to the difficulty of coping and 
adjusting successfully to this burdensome health status. Nurses need to be aware of 
adverse brain-related outcomes in this patient population, and to ensure that optimal 
treatment interventions encompassing the physical, emotional (including psychological 
counseling and treatment) and social domains are in place to prevent or reduce the impact 
of cognitive dysfunction on patients with PAH.
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Access to this timely and optimal treatment can be facilitated by nursing case 
managers. Hesselgrave (2003) notes that there are challenges coming from within the 
health care system
... that focus on cost-containment [and] perpetuate the gap between patients and 
the care they need... .Patients report difficulty in getting referrals to [specialists], a 
matter they believe stems from the lack of understanding [about PAH] by plan 
administrators, payors and primary clinicians (p. 65).
The role of the case manager is to monitor the use of resources by patients who may 
require excessive support. Hesselgrave (2003) posits that in that role, case managers 
become “the liaison to ensure access to the thorough and attentive clinical experts that are 
necessary. .. [And] get payor clients to realize that the right medical care at the right time 
is essential [for patients with PAH]” (p. 69). These advocacy efforts can improve patient 
outcomes and reduce the cost of treatment. Through these efforts, the nursing case 
manager can help to alleviate the anxiety felt by patients throughout the period of 
diagnosis and treatment of PAH.
Nurses must support patients in the use of healthy coping strategies to manage the 
uncertainties encountered by having PAH. In the study by Flattery et al. (2005), coping 
methods that patients use were identified. Seeking information about their disease from 
internet web sites is common. Because nurses are instrumental in providing information 
and education to patients, nurses must direct patients and their families to internet sites 
that provide accurate and up-to-date information about PAH, especially during the period 
when diagnostic testing is taking place or when changes are being made in treatment. A 
popular and reliable website for patients and their health care providers is maintained by
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the Pulmonary Hypertension Association (PHA) at http://www.phassociation.org. Nurses 
must be prepared for ensuing questions and concerns that patients may have as a result of 
their investigations, and be able to provide direction to address those matters in light of 
what is known about each patient’s health status and treatment plan.
The PHA (2010) webpage is comprehensive. On it, the PHA hosts a wealth of 
information and resources for patients, their caregivers, and health care professionals in 
the United States. Written materials are also available. The webpage has a listing of 
national, regional and local support groups for patients. Sister organizations exist 
internationally, and can be accessed at the provided PHA website address. Becoming 
familiar with this organization and its website may prove beneficial for professional 
development and research, and for assisting nurses to help patients seeking information 
about PAH.
Traiger (2007) notes that nurses are instrumental for giving patients and families 
the information they need to understand the disease process and “all the available and 
appropriate treatment options” (p. 33), including medications, research protocols, surgical 
options and lung transplantation. Patients and their families need to have any 
misinformation clarified. When a treatment plan is made, nurses will teach the patient 
and caregiver about therapy management, the expected effect of treatment and any side 
effects. They need information about symptom management. Patients receiving IV 
prostaglandin therapy require education about pump use and implanted catheter care, as 
well as what to do in any emergency. Patients getting IV therapy require regular contact 
from nurses who specialize in the assessment and education of patients on IV
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prostaglandins (Traiger, 2007). These specialized nurse educators have a crucial role in 
helping patients comply with the demands of IV treatment for PAH.
Spirituality has a role among the coping strategies found by Flatteiy et al. (2005). 
While making significant life changes in order to maintain a quality of life with PAH, 
patients may increasingly rely on psychological and spiritual resources for support during 
those times of adjustment. According to Schirm (2009), spirituality is defined broadly in 
the nursing literature “as embracing Tove, compassion, caring, transcendence, 
relationship with God, and connection of body, mind and spirit’” (p. 145). Spirituality as 
a belief-system affects all aspects of a person’s well being. Thoughtful evaluation by 
nurses of the extent and type of belief system that a patient has, along with assuring the 
ongoing provision of needed resources for spiritual support will help patients effectively 
cope with their changing status.
There is no cure yet for PAH. Presently, the aim of treatment is palliative—to 
lengthen survival time, relieve symptoms and improve quality of life (McKenna et al., 
2006). However, the cost of IV prostaglandin therapy has impacted not only the ability of 
patients to pay for the drugs (Lowe, et al., 2004; Rich, 2000; Traiger, 2007), but also the 
ability of these vulnerable patients to access hospice care when it is most needed 
(Traiger, 2007; Wryobeck et al., 2007). Survival rates for patients with PAH and 
circulatory collapse given CPR is poor (Hoeper, et al., 2002). Recognizing this, nurses 
and other health care providers need to begin discussions about issues related to end-of- 
life care with patients early in the course of treatment so there is time for decision­
making. Nurses are committed patient advocates, and creative solutions must be designed
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and tested so that patients on this form of treatment continue to receive compassionate, 
holistic care during their final days.
Researching the lived experience of patients receiving IV prostaglandin therapy 
for PAH remains a viable nursing endeavor, especially given that nursing is focused on 
caring science (Watson, 2008) and has developed expertise using qualitative 
methodology to explore questions in patient care (Streubert-Speziale & Carpenter, 2007). 
Such studies will contribute to nursing knowledge a sharpened understanding of the 
issues facing patients and enable nurses to closely match nursing interventions to support 
what matters most to this patient population.
Limitations of the Current Study 
As a researcher, I was disappointed that I was unable to carry my proposed research 
forward. However, my experience prompted me to think about why I experienced 
recruitment failure. Chin Feman, et al. (2007) report that “recruitment challenges are 
reported to be the cause of 45% of study delays with delays often exceeding 6 months” 
(Introduction, l).What strategies are being used by other investigators to recruit study 
participants? How do the HIPAA Privacy Rule and the federal rule for Protection of 
Human Subjects (Common Rule)—the two federal laws that mandate how personal 
health information can be used and mandate the required consent process (Rothstein, 
2005)—affect the recruitment process? What future strategies may be useful to recruit 
participants from populations with a rare disease and/or treatment?
Regulatory Constraints on Research Recruitment
Prior to the implementation of the HIPAA Privacy Rule in 2003, the regulation of 
privacy issues in research involving human subjects was the domain of the Common
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Rule. This rule was developed in response to the Belmont Report of 1978, which became 
the basis for the Common Rule. The report “articulated the ethical principles upon which 
standards of ethical conduct in research are based; beneficence, respect for human 
dignity, and justice” (Polit & Beck, 2004, p. 143). The Common Rule identified the 
means by which ethical conduct in research would be assessed and applied.
On April 14, 2003, the HIPAA Privacy Rule became effective. The new Privacy 
Rule and the older Common Rule were intended to be complementary in regulating 
research privacy. Both rules define research “as a systematic investigation, including 
research development, testing, and evaluation designed to develop or contribute to 
generalizable knowledge” (45 C.F.R. § 164.501 [2004] {Privacy Rule}; 45 C.F.R. § 
102(d) [2004] (Common Rule} as cited in Rothstein, 2005). But there are areas where 
the rules diverge, which has caused some confusion, frustration and misunderstandings 
by researchers, research subjects and institutional review boards (Gostin & Nass, 2009; 
Marsh, McMaster, Parvizi, Katz & Spindler, 2008; Ness, 2007; Rothstein, 2005) since the 
Privacy Rule has been implemented.
To sort through this confusion, it is helpful to understand that the general 
provisions of the Privacy Rule and the Common Rule are different in important respects. 
According to Rothstein (2005), they differ in coverage, what is protected, and in 
oversight. The Privacy Rule applies to:
Certain health providers, health plans and health clearinghouses and their business 
associates. The Common Rule applies to researchers receiving federal financial 
support... [that are performing] research conducted in contemplation of 
submission to the Food and Drug Administration... [that are performing] research
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[representing] an institution that has signed a ‘multiple project assurance’ with 
Health and Human Services (HHS), [meaning that the institution promises] to 
comply with the Common Rule in all research, regardless of the funding source 
(p. 155).
The Privacy Rule is designed to maintain the privacy of protected health information in 
its use and disclosure by the covered entities listed above. The Common Rule is designed 
to protect the welfare of human research subjects, which includes the privacy of the 
participants and the confidentiality of the data they provide. If the Privacy Rule is 
violated, the complaint is directed to the Office for Civil Rights of HHS, which is 
responsible for its oversight. The primary responsibility for ensuring compliance with the 
Common Rule lies with the IRB of the institution performing the research. The IRBs, in 
turn, are overseen by the Office for Human Research Protections that is within HHS 
(Rothstein, 2005).
There are also notable discrepancies between the Common Rule and the Privacy 
Rule which have led to inconsistencies in research oversight. A problem consistently 
identified by researchers is about the discrepancy between the rules regarding preparation 
for research (Gostin & Nass, 2009; Marsh et al., 2008; Ness, 2007; Rothstein, 2005). 
Under the Privacy Rule within the preparatory to research provision, a covered entity 
may permit a researcher who works for that covered entity to review protected health 
information (PHI) in preparation for research—perhaps to aid study recruitment—  
without prior permission given by the individual for access to his or her personal PHI.
The preparatory research provision allows such “a researcher to identify prospective 
research participants for purposes of seeking their Authorization to use or disclose [PHI]
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for a research study” (National Institutes of Health, 2007, Activities Preparatory to 
Research, 1 2). Under the Common Rule however, all recruitment activities are 
considered an element of research. Therefore, the research protocol must first be 
approved by the IRB before recruitment activities of any kind may take place. In this 
instance, the Privacy Rule permits conduct that is not allowed under the Common Rule, 
creates an artificial distinction between researchers who are internal or external to a 
covered entity, and offers fewer protections than the Common Rule provides (Gostin & 
Nass, 2009; Rothstein, 2005).
According to findings by Ness (2007) and Wolf and Bennett (2005), the primary 
focus by the Privacy Rule on consent has diminished the ability of investigators to recruit 
participants, increased the time required to complete a study, and has added to the cost. 
Gostin and Nass (2009) points out that the “universal requirement for consent... creates 
selection bias, which limits the generalizability of results and leads to invalid 
conclusions” (p. 1374). Among several recommendations made in the article by Gostin 
and Nass to address rule discrepancies, was a proposal that there be made by HHS 
“consistent rules for activities conducted in preparation for research, such as identifying 
and recruiting potential research participants” (p. 1374). Clarification of the rules will 
make a level field for researchers not employed by a covered entity, may help to reduce 
study delays, and facilitate resource utilization.
Interventions to Address Recruitment Constraints Suggested by the Literature
Since implementation of the HIPAA Privacy Rule, investigators are finding ways 
to stimulate recruitment into research studies that meet the requirements of the Privacy 
Rule and improve the recruitment of participants into studies from all segments of the
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population, including those that have historically been poorly represented (Fouad, et al., 
2004). Because many issues influence whether a person chooses to participate in research 
or not, investigators have used several approaches to help stimulate participant 
recruitment. Sometimes the strategies have been used alone, and at other times, 
synergistically (Chin Feman, et al., 2008; Fouad, et al., 2004; Richesson et al., 2009). 
Fouad, et al. described study-wide recruitment efforts and site-specific recruitment 
strategies that were effective based on their experience with the Women’s Health 
Initiative (WHI).
The WHI was a large, national, multicenter study that investigated the major 
causes of death and disability among postmenopausal women. The investigators were 
challenged to recruit a sufficient number of women from diverse populations, including 
older women and women from ethnic minorities who are typically underrepresented in 
clinical studies. The investigators evaluated the scientific literature to determine why this 
problem exists, and used their findings to formulate specific recruitment strategies to 
stimulate recruitment to the study at the national and local levels.
The WHI study involved 40 clinical centers across the United States including 
Hawaii but not Alaska. Of the 40 centers, 10 were classified as minority centers and were 
in areas where minority populations live. The WHI used the national media for publicity 
about the study as well as a mass mailing package about the study with contact 
information for locally funded centers. Each individual center devised materials to appeal 
to its own population such as culturally specific materials or materials aimed at women 
with specific demographics, like age. Recruitment coordinators targeted public databases 
such as insurance companies and large corporations to find possible participants. Mass
52
media strategies included the use of paid newspaper advertisements, newspaper and 
periodical articles about the study, and radio and television public service announcements 
at both national and local levels.
Investigators also used direct physician and other health-care provider contact to 
request referral of potential participants, worksite recruitment, and a program that asked 
enrolled participants to, with the permission of the participants’ friend, to provide that 
friend’s name to the investigators as a possible recruit. Participants were given a gift 
certificate to a retail store for each friend recruited. Community outreach activities 
included health fairs and church presentations. In some instances, transportation was 
provided to a clinical site, and Saturday hours were instituted. Responses were generous 
because individual clinics tailored their recruitment strategies to targeted populations. 
Once recruited, respondents underwent a series of face-to-face screening events to 
introduce the study, determine interest levels, establish trust and ascertain eligibility.
Overall, recruitment to the WHI was successful. Fouad, et al. (2004) found that 
the key to recruitment “is in getting the information out to the target audience: making 
the first contact and providing information” (p. 350). The investigators also noted that, 
for minority recruitment, “the [reported] distrust [of the medical community by minority 
groups] can be overcome by interpersonal contact through community outreach, referral, 
and other culturally appropriate recruitment strategies” (p. 351).
Chin Feman, et al. (2008) conducted an NIH funded study “testing the effect of 
the patient-physician relationship and acupuncture on irritable bowel syndrome patients 
at a large tertiary care hospital in a major metropolitan area” (p. 242). Following “four 
months of recruitment and one enrollment” (p. 243), the investigators re-evaluated their
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recruitment plan. To recruit the number of participants needed for the study successfully, 
adjustments were made.
The researchers used several recruitment strategies. Strategies included the use of 
mass media, including paid newspaper and television advertisements, free classified 
advertisements in university newspapers, and the strategic placement of fliers. Not only 
were fliers placed in areas that might be noticed, but at different, scheduled times as well. 
A similar strategy was used for placing advertisements on mass transit. The internet was 
used. Short text advertisements were placed for free on craigslist.com, clinicaltrials.gov, 
and on a disease-specific website. The researchers also maintained a small website for the 
study. Informational materials were delivered to local, private gastroenterology practices. 
Several local private psychology and general medicine practices were notified of the 
study as well.
Chin Feman, et al. (2008) used a novel equation to determine the efficacy of each 
recruitment strategy, based on the ratio between fractional cost to fractional enrollment, 
called the Efficacy Index (El). From the calculations. Chin Feman, et al. found that 
physician referrals and posting fliers were efficient methods for recruitment to this study. 
Internet advertisements were also efficient, but website recruitment was not. Using mass 
transit advertisements and newspaper advertisements was the least effective methods, but 
some respondents did report that they had seen information about the study in more than 
one place.
Richesson et al. (2009) evaluated the impact of an automated, administrative 
registry on enrollment and participation in advertised clinical research studies. The 
registry consists of individuals who have self-identified one or more rare disease entities.
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and who have acknowledged a willingness to be contacted for possible enrollment in 
clinical research studies. This registry, the Rare Diseases Clinical Research Network 
(RDCRN), actively began accepting enrollment via the internet in 2004 and sending 
automated messages by e-mail about clinical trials to its enrollees since 2007. Automated 
methods like this registry "... offer an inexpensive approach to communicating with 
potential study participants, and are scalable to communicate with ever-growing numbers 
of individuals without a corresponding increase in resources” (p. 60). The online patient 
registry can be an important tool for clinical research by increasing the efficiency of 
research recruitment.
The RDCRN is diverse by disease process but the majority of enrollees are 
Caucasian, which, according to Richesson et al. (2009), may “reflect the demographics of 
those having these diseases, [may reflect] the likelihood... [of] better access to rare 
disease specialists for disease diagnosis and care... or access to the internet” (p. 60). The 
authors believe that further evaluation of the registry enrollment is needed to determine 
whether the composition is generalizable to the greater population affected by rare 
diseases or if there is access or other barriers to enrollment.
Conclusions Regarding Recruitment Literature and Application to Current Study 
An ideal approach to research recruitment produces a number of calls and rapid 
enrollments with little effort by the recruitment staff and with the least cost (Chin Feman, 
et al., 2008). No one method works to stimulate recruitment in every situation and 
recruitment difficulties increase when researchers want to investigate the problems 
associated with rare illnesses and treatments (Richesson et al., 2009; Steinke, 2004). 
Among the ways that potential participants have learned about clinical trials is by
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physician referral, through registries, fliers and brochures, the media; including 
television, newspapers and the radio, community advertising, the internet, from a friend, 
or by a cold call (Chin Feman et al, 2007; Fouad, et al., 2004; Richesson et al, 2009; 
Steinke, 2004). Fouad, et al. (2004) noted recruitment success in some populations when 
soeioeconomic issues were addressed and strategies were individualized to communities. 
While the literature reviewed involved two large studies that sought participants from the 
general public and one that involved the recruitment of participants with rare diseases, 
elements of their recruitment strategies could be used to stimulate recruitment into many 
kinds of investigations.
The current study was to involve a limited population defined by the relatively 
rare condition of PAH. Additionally, the defined population was to be receiving a 
specific and difficult treatment for their disease. Related to working as a staff nurse at a 
local, tertiary care hospital system, this researcher was aware that within the system there 
was an outpatient clinic that enrolled members of the population of interest. After 
contacting the clinic’s nurse manager to learn about the number of patients seen with this 
diagnosis and treatment, my thesis committee chairperson and I believed the study would 
be feasible despite the small number of potential participants in the clinic patient 
population for this qualitative investigation.
To comply with the HIPAA Privacy Rule for research, an opt-in approach to 
recruitment was devised. Potential participants were to be given a recruitment package by 
clinic staff, and as the researcher, I would follow-up only with those who returned the 
letter. After developing the study proposal, I sought the approval of the IRBs for my 
proposed study from both my university and from the hospital system. Ultimately, despite
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regular contact with clinic staff to remind them of the study, their diligent effort, and a 
revision of the protocol that allowed this researcher to meet with interested recruits on 
site, recruitment failed. I believe that I underestimated the resources that I would need for 
recruitment.
In addition to the local clinic from which I sought participants, there is an 
important resource that may have been helpful for recruiting participants—the PHA 
internet website at http://www.phassociation.org. Not only does this virtual community 
provide patient information and support as described previously, there is support for the 
practice of health care professionals in regards to the diagnosis and treatment of PAH, 
too. Researchers may post information to the online lay community about opportunities 
to participate in research (Pulmonary Hypertension Association, 2010). Using this 
resource to cast a wider recruitment net might have helped to prevent recruitment failure 
for this study.
Disease registries have been used to assist the clinical research process for many 
years. According to Richesson et al., (2008), such registries have been used since the 
1940s in cancer research. Because of the recruitment challenge of identifying potential 
participants for a given study, the idea of maintaining lists of affected persons who have 
an interest in participating in clinical research is an appealing method for researchers to 
use. These managed lists of potential research subjects are seen to potentially ease 
recruitment and increase the likelihood of acquiring an adequate representative sample 
from which to generalize study results.
There are two types of registries. The first type is called an administrative 
registry. Individuals with particular diagnoses may join this kind of registry to receive
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personal notification of research projects they may be eligible to participate in. 
Researchers can approach the registry for assistance recruiting people to participate in 
their studies (Richesson et al., 2008). The second type is population based.
Population based registries collect disease-related data, either from self-report or, 
with individual consent, from medical records. This information is used for data mining, 
generating research hypotheses, and secondary research questions (Richesson et al, 
2008). The Registry to Evaluate Early and Long-term PAH Disease Management 
(REVEAL) is a population based registry for patients with WHO group I PAH (McGoon, 
et al., 2008). It is a multicenter, observational, US-based registry designed to study the 
disease course and disease management over time of patients with PAH. Among its 
objectives is “to identity clinical predictors of short-term and long-term outcomes”
(Table 1, p. 924), and, in anticipation of unseen research goals not anticipated at the 
study’s inception, is the objective “to collect timely and relevant data that will assist in 
the evolving research needs of the PAH community” (Table 1, p. 924). Investigating 
access to this registry may have also helped to provide a pool of participants for my 
proposed research. I noted that, in the list of principal investigators were local individuals 
from whom this researcher might have been able to request information about registry 
access for the proposed research. While examining the literature on a topic of interest for 
research, it may help recruitment efforts to collaborate with other investigators sharing 
interest in a study topic.
Given the impact of recruitment delays and failure can have on worthwhile 
projects (Chin Feman, et al., 2008), novice researchers should become familiar with 
currently effective recruitment methods and strategies for their research projects. While
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nurses may possess a general awareness of sample recruitment strategies (Polit & Beck, 
2004), nurses are not educated about the kinds of marketing strategies that can increase 
the efficacy of recruitment. Consideration should be given to expanding the topic of 
recruitment methods in nursing research texts and directing students to research articles 
addressing recruitment methods appropriate to their research.
There is a burden placed on nurse educators and experienced researchers 
mentoring novices to ensure that the student is familiar with federal rules affecting 
research and participant privacy, including the Common Rule and HIPAA Privacy Rule. 
A useful approach to ensuring such familiarity is to take a course such as the ones offered 
by the Collaborative Institutional Training Initiative (CITI) at www.citiprogram.org. The 
CITI courses offer a menu of research ethics education to investigators. Courses are 
generally required for researchers in institutions where human or animal research takes 
place, and certification is issued to those satisfactorily completing the educational 
modules.
Summary
Despite encountering a failure of recruitment into the present research study, from 
the synthesis of current literature about PAH, conclusions about nursing care and 
interventions have been made that are based on the present state of science regarding the 
experience of enduring the symptoms of PAH and its treatment. Additionally, the 
usefulness of a phenomenological approach for increasing our understanding of patients’ 
experiences in order to better provide nursing care to them as they undergo new 
treatments or use technology for their chronic illness has been discussed. A descriptive 
phenomenological approach helps nurses gain needed insight into the human experience
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of these phenomena, enabling us to more fully focus on and support what matters most to 
our patients.
Completing a research project can be a difficult hut rewarding endeavor. There 
can also be disappointments, including research delays and recruitment failures.
Obstacles to recruitment and strategies for overcoming these obstacles were discussed. It 
is hoped that by sharing this experience, others investigators will have awareness not only 
of the challenges of participant recruitment but of some workable strategies to help 
ensure success in research efforts.
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APPENDIX A
Table 1
Classification o f Pulmonary Hypertension: Third World Conference on Pulmonary
Hypertension', 2003; Venice
Group I—Pulmonary arterial hypertension (PAH)
Idiopathic PAH 
Familial PAH 
PAH associated with;
Collagen vascular disease
Congenital systemic to pulmonary shunts (large, small, repaired, or unrepaired) 
Portal hypertension 
HIV infection 
Drugs and toxins
Other (glycogen storage disease, Gaucher disease, hereditary hemorrhagic 
Telangiectasia, hemglobinopathies, myeloproliferative disorders, splenectomy) 
PAH associated with significant venous or capillary involvement:
Pulmonary veno-occlusive disease 
Pulmonary capillary hemangiomatosis
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Group II—Pulmonary venous hypertension 
Left-sided atrial or ventricular disease 
Left-sided valvular heart disease
Group III—Pulmonary hypertension associated with lung diseases and/or hypoxemia
Chronic obstructive pulmonary disease
Interstitial lung disease
Sleep-disordered breathing
Alveolar hypoventilation disorders
Chronic exposure to high altitude
Group IV—Pulmonary hypertension due to chronic thrombotic and/or embolic 
disease
Thromboembolic obstruction of proximal pulmonary arteries 
Thromboembolic obstruction of distal pulmonary arteries 
Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
Group V—Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels 
(adenopathy, tumor, fibrosing mediastinitis)
Note. From “Clinical classification of pulmonary hypertension” by Simmoneau, Galie, 
Rubin et al., 2004, The Journal o f the American College of Cardiology, 43, p. SIO. 
Copyright 2004 by Elsevier, reprinted with permission (Appendix L).
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APPENDIX B
NYHA/WHO Functional Classification for Pulmonary Arterial Hypertension
APPENDIX B
Table 2
NYHA/WHO Functional Classification for Pulmonary Arterial Hypertension
Class I No limitation of usual physical 
activity. Ordinary physical activity 
does not cause undue dyspnea or 
fatigue, chest pain or near-syncope. 
Asymptomatic
Class II Slight limitation of physical activity; 
no discomfort at rest, ordinary activity 
causes undue dyspnea, fatigue, chest 
pain, or near syncope.
Class III Marked limitation of physical activity; 
no discomfort at rest, but less than 
ordinary physical activity causes 
undue dyspnea, fatigue, chest pain, or 
near syncope.
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Class IV Inability to perform any physical
activity without symptoms. Signs of
right ventricular failure or syncope.
Dyspnea and/or fatigue may be
present at rest, discomfort increased
by any physical activity.
Note; The NYHA/WHO modification (Rich, 1998, cited in Traiger, 2007).
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Permission Letter, PAH Clinic
APPENDIX C 
Permission Letter, PAH Clinic
Permission to Conduct Research, Spectrum Health Heart Failure and PAH Clinic
D w onber 23.2009
Whom It May O n cem .
I have been contacted by Phyllis Boone, .student from ( la n d  Valley State I miversly. to 
have the Spectrum Health Heart Failure. Tran.splani and Fuimonaiv Uyiterlensnm CImic 
asiisi in her education requirements bv participating in a research project. I have 
reviewed the infomtatkm/clmie requirements wrJi her and agree to allow Phyllis to move 
forward with this research protect.
Please dc not hesitate to call me if  you have any questions.
Keiçectlüliy,
»4, WS. M*«9e'
nrw eiiw e Cartesosr S Seii»>it9liQii W  
• W - f f l i u i t f F a n s p la w iP i i lm o n s f v H v p w c n s o n t*  ies 
Sped ru riH ea ltrG 'w id fi
a W N K W ;  Mi « 5 2 5  
eiMaW5P«r«MW 
tKeiWIM'K,
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APPENDIX D 
Recruitment Letter
APPENDIX D 
Recruitment Letter
301 Michigan St. NE 
Grand Rapids, MI 49503-3314
Dear Patient:
The purpose of this letter is to invite you to participate in a clinical study about 
what it is like for you to take IV medicine to treat your Pulmonary Arterial Hypertension. 
Talking about your experience can help nurses understand what this is like for you in 
order to better meet special needs you may have. Other patients taking the medicine 
might have the same kinds of experiences, and your story may help nurses to help them 
as well. The newness of this treatment makes the need for this kind of research greater.
This study asks for your participation in a single interview, which will take place 
in your home or place of residence. There will be one researcher, who is a graduate 
student at Kirkhof College of Nursing at Grand Valley State University. The interview 
will take 45 to 60 minutes. It will be electronically recorded and notes will be taken. You 
will be able to stop the interview at any time if you do not feel well or become tired. Your 
identification will remain confidential. Unique situations that may reveal who you are 
will be removed, and specific statements will not be linked to you. When the study is 
finished, the research findings will be shared with the clinic staff, students at Grand 
Valley State University, and with nurses working in hospitals, clinics and in education. 
The findings may be shared at a nursing conference.
If you want to learn more, or if you are interested in participating in this study, 
mark the “Yes blank below. Then return this letter with your contact information below
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in the stamped, self-addressed envelope provided. After I receive your letter, I will 
contact you within 3 business days to answer questions and set up a time for the 
interview. You are welcome to contact me by e-mail. Thank you for thinking about 
taking part in this study.
Sincerely,
Phyllis Boone, BSN, RN, MSN student
Kirkhof College of Nursing at Grand Valley State University
boonep@mail. gvsu.edu
Yes, I am interested_____
Name; Date of Birth:
Phone Number: (___ ) _________________  E-mail:
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Text Message of the Reminder Postcard
APPENDIX E
Text Message of the Reminder Postcard
This is a reminder to you about the study of what it is like for you to take 
intravenous medicine for your PAH. If you have not done so already and would like to be 
part of this study by sharing your story, please fill out and return the letter in the envelope 
that you were given at the PAH clinic. If you have any questions about the study, you can 
contact the primary researcher at the e-mail address or the phone number that is given in 
the letter you received at the clinic. She will be happy to help you. Whether you have 
already returned the letter or decided that you cannot participate, we’d like to thank you 
for considering being a participant in this study.
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Confirmation Letter
APPENDIX F 
Confirmation Letter
301 Michigan St. NE 
Grand Rapids, MI 49503-3314
Dear Participant,
Thank you again for being willing to take part in this research study. We are
meeting together on Date:_________ , Time:_______at your home or place of residence
for a 45 to 60 minute interview. There are some things that will help to make our time 
together productive. This letter will give you some helpful hints to meet that goal.
A copy of the research consent form and HIPAA authorization for the release of 
personal health information for research has been sent to you with this letter. Before we 
meet, please take some time to read the forms. It is very important for you to understand 
the messages there before the interview starts. You may write down any questions you 
have for me about the forms. You may call me or e-mail your questions or concerns to 
me using the contact information below. We will sign the forms together just before the 
interview will start.
Then I will set up some equipment so that the interview can be digitally recorded. 
When the interview begins, please speak as clearly as you can. It will help if we can work 
together in a quiet room that is comfortable for you. It will also be helpful to reduce 
interruptions during the interview. Switching off electronic devices like cell phones will 
be important during our time together.
The physical effort required by the interview may be tiring for you. You may stop
the interview at any time you believe that it is too hard to finish. For example, you might
have too much physical discomfort like shortness of breath. I may stop the interview if I
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see that you are having trouble. You may be asked if  you would be willing to re-schedule 
an interview at another time.
The process of in-depth interviewing may bring up areas that cause emotional 
discomfort for you. I will make every effort to minimize such occasions. The interview 
may expose some new areas of difficulty for you-such as difficulty managing symptoms, 
the medication and equipment, financial issues or support problems. You will be given a 
contact number for the Heart Failure, Transplant and Pulmonary Hypertension Clinic, 
and you will be directed to the appropriate person that can help you address your 
problem.
The information we nurses learn in this study may help us to better understand 
what life experience while on IV medicine for treatment of pulmonary arterial 
hypertension is like for you and for our future patients. It may help us develop new ways 
to care for patients who share your situation. Thank you for your time and energy that 
will help to meet these goals.
Sincerely,
Phyllis Boone ESN, RN, MSN Student
Kirkhof College of Nursing at Grand Valley State University
boonep@mail.gvsu. edu
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APPENDIX G
Research Informed Consent & HIPAA Authorization for Release of Health 
Information for Research Purposes 
Research Consent For:
The lived experience; Pulmonary arterial hypertension and intravenous 
prostaglandin therapy
Protocol number:
Principal Investigator: Phyllis D. Boone, ESN, Graduate Nursing Student 
Affiliation: Kirkhof College of Nursing at Grand Valley State University 
“You” refers to the patient.
Introduction:
You are being asked to be a part of a clinical research study. Clinical research is 
the study of human diseases and associated problems, of possible treatments, or 
ways to diagnose disease. It is up to you to decide whether to be a part of a 
research study, or not. To help you make this decision, you need information 
about the study’s possible risks and benefits and alternatives. This process is 
called informed consent.
This consent form gives detailed information about the research study. The 
researcher will discuss this information with you. You can also ask any questions 
you have. After you have received this information, if you decide to participate in 
this study, you will be asked to sign this form. You will be given a copy of the 
signed form.
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Nature and Purpose of this Study:
The purpose of this research study is to learn what it is like for you to live with IV 
treatment for pulmonary arterial hypertension (PAH). During an interview in your home 
or place of residence, you will be asked to tell the student researcher about your 
experience. The study is being done to help nurses understand what it is like for you and 
others like you to have this treatment. Your story can help nurses provide care that 
supports the unique needs that you and others being treated with these medicines may 
have.
To be a part of this study, you must;
1. Be age 18 years or older, able to speak and understand the English language, be 
able to think about a question and discuss your answer, and have the time needed 
for an interview.
2. Be willing to participate in a private interview.
3. Be medically stable. This means you are not in the hospital.
4. Have a Class III or Class IV Functional Health status. This is based on a
diagnosis from your health-care provider.
5. You must be receiving IV epoprostanil (Flolan®) or IV treprostinil (Remodulin 
®) treatment for pulmonary arterial hypertension (PAH).
You are being asked to participate in this study because you are receiving IV treatment 
with epoprostanil or treprostinil for your pulmonary arterial hypertension (PAH).
It is expected that 3 to 5 people will join this study.
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Study Procedures:
You are being asked to participate in one interview. The topic will be about your 
experience living with IV treatment for your pulmonary arterial hypertension (PAH). The 
private interview will last 45 to 60 minutes. The interview will take place in your home 
or place of residence.
The interviews will be audio-taped and written out later. You will be given a participant 
number which will be the only identifier used in the recording, the written information 
and in the final study report.
Any information that identifies you specifically will be used only for contacting you to 
arrange for the interview. It will be used to access your medical record after you give the 
researcher your permission to see your medical records.
What Information is Needed from mv Medical Record?
Your medical record will be used to obtain your health history. This means that your past 
health history, the age at which you were diagnosed with PAH, and what caused you to 
have PAH, will be obtained.
The results from tests that were used to make sure of your diagnosis of PAH will be 
obtained. Those tests might include ultrasounds, heart catheterizations, biopsies, EKGs, 
lung function tests, 6 minute walking tests, and pulse oximetry, blood gas tests or other 
lab tests.
Information about your health since you started taking IV medicine will be obtained. This 
information includes the name of the drug you are taking and why the drug was 
prescribed for you. Information about your health status at the time you started the 
medicine and what it is like now will be gathered. The results of recent EKGs, 6 minute
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walk tests, pulse oximetry readings, blood gas readings and other lab tests will be 
gathered as well.
Risks, Discomforts and Vulnerabilities:
The in-depth interviews may bring up areas that are hard for you to think about. They 
may cause emotional uneasiness. Every effort will be made on the part of the nurse 
researcher to minimize such occasions. You will be given a list of people that you can 
contact at the PAH clinic if you need help managing this uneasiness.
The physical effort needed to do the interview should be about the same as other 
discussions, but it might be tiring for you. You may stop the interview at any time if  you 
think it is too hard to finish because of physical concerns such as being out of breath. You 
may be asked to finish the interview at another time.
If many words typical of your discussions are used in the research report, it is possible 
that you would be recognized. Every effort will be made to disguise situations or words 
that might show your identity.
Potential Benefits:
You may not benefit from your participation in this study. The information that nurses 
learn in this study may help us to better understand what life is like for you and for our 
future patients who are on IV medicine for treatment of pulmonary arterial hypertension. 
The information you share may help us develop new ways to care for patients who share 
your situation.
Costs/Pavment for Study Participation:
There are no costs to you or to your insurance company for participating in this study. To 
thank you for your time and for sharing your experiences, a gift card valued at $15.00 
from Meijer will be provided to you at the end of the interview.
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Voluntary Participation:
Joining this study is voluntary and solely your decision. You may refuse to be a part of 
this study. You may also stop being a part of this study at any time. Refusing to 
participate or stopping your participation will involve no penalty or loss of benefits to 
which you are otherwise entitled. The nurse researcher may also stop your study 
involvement at any time without your permission if she believes it to be in your best 
interest, or if the study is ended.
Confidentiality (PrivacvJ:
Your privacy is respected. It is important for you to understand that we cannot promise 
complete confidentiality of your medical information if you decide to be a part o f this 
study. People who might look at your medical information are:
1. The student nurse researcher and her study advisor,
2. Representatives from Grand Valley State University,
3. Representatives from Spectrum Health,
4. The Human Research Review Committee at Grand Valley State University,
5. The Spectrum Health Research and Human Rights Committee, and/or
6. Representatives from governmental regulatory agencies.
Those listed above may see parts of your medical records related to this study and, 
therefore, will see your name and other personally identifiable information about you. 
They must also preserve confidentiality (privacy).
The information collected for this study will be sent to and stored at Grand Valley State 
University. It is the property of the University and you will not be able to get it back.
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Your information is protected by (1) using only your participant number on the 
information we are storing; (2) separating papers with your contact information and name 
from the information that is labeled with your participant number; (3) storing the 
information and papers in a locked file and locked room; (4) limiting the people who 
have access to it; and (5) limiting how the information may be used. Details about 
permitted uses and disclosures of your information are described under the HIPAA 
Authorization section of this document. Your name will not be shown in any reports or 
publications from this study, unless you first give the nurse researcher your consent to 
use your name. It is expected that the study will be published as the nurse researcher’s 
thesis, and that she will present the findings in presentations and professional meetings. 
She may also publish a shortened version of the study in ajournai for nurses or other 
health care professionals. If you would like a summary of the study, please initial the line 
after you sign this consent.
Your privacy and confidentiality will be kept as required by law.
Your access to your medical records on file at Spectrum Health will not be changed by
this study.
A copy of the information collected for this study will be kept by the student nurse 
researcher at her home. Only your participant number will be written on this information. 
Your name and all other identifying information will not be allowed and will be removed 
from the documents.
Electronic copies of audio recordings will be kept at her residence for the time needed to 
analyze the information you give during the interview. After this is completed, the audio 
recordings will be given to Grand Valley State University. They will be stored at the 
University.
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The audio recordings in electronic format will be kept in locked files in offices at Grand 
Valley State University for a period of three years, after which they will be destroyed.
HIPAA Authorization for Release of Health Information for Research Purposes
As part of this research study, you are being asked to release your health information.
The Health Insurance Portability and Accountability Act (HIPAA) allows a hospital or 
doctor’s office to use or release protected health information (PHI) for the purposes of 
treatment, payment or health care operations. Health care operations activities include 
such things as audits, quality assurance initiatives, audits from insurance companies, 
treating physicians, legal advisors, insurers and data storage companies.
A HIPAA authorization gives permission from you to use or release your PHI for 
research purposes.
A HIPAA authorization is in addition to your consent to participate in this research study.
1. What will you do with this information and why am I being asked to allow 
you to release this information?
This information will be collected and entered in a database along with the 
information from other people taking part in this study. This information will be 
used to confirm identifying information, to confirm your diagnosis and treatment.
2. What are you asking to release?
To complete this research study, information about you needs to be collected.
This information may include;
a. Your date of birth, name, contact information and medical record 
number.
b. Existing medical records and medical history.
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3. Who may use or share your protected health information for this research 
study?
a. Grand Valley State University Kirkhof College of Nursing staff 
and members of the Human Research Review Committee of Grand 
Valley State University,
b. Spectrum Health staff, employees or other agents,
c. The Spectrum Health Research and Human Rights Committee,
d. Agencies that accredit the university, the hospital or the research 
programs.
Once your protected health information has been disclosed it is possible that anyone who 
receives that information may re-disclose it. Because some of these individuals who 
receive your protected health information may not be required by law to keep your 
information confidential, we cannot guarantee that your information will not be released 
or made available to another party once it leaves Grand Valley State University or 
Spectrum Health. Therefore, we share your information only if necessary and we use all 
reasonable efforts to request that those individuals who receive your information take 
steps to protect your privacy.
4. How long will this authorization last?
This authorization has no expiration date.
5. Can I stop my information from being used?
You can cancel this authorization at any time. Your cancellation must be in 
writing. Once you cancel your authorization, we will stop collecting your medical
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information. Any information that was collected before you stopped your 
authorization will still be used as described above.
If you decide to stop the collection of your protected health information for this 
study, you must send a written, signed and dated notice to the principal researcher 
at the address provided below:
Phyllis Boone, BSN, RN, MSN student
Kirkhof College of Nursing at Grand Valley State University
301 Michigan St. NE
Grand Rapids, MI 49503
6. What if I do not authorize you to collect and release my health information? 
If you decide not to authorize release of your health information as part of this 
study, your decision will in no way affect your medical care or cause you to lose 
any benefits to which you are entitled.
You cannot participate in this research studv if vou do not authorize the use or 
release of vour PHI.
7. When will my PHI collected for this study be destroyed?
Your PHI will be destroyed when the research project is completed.
Contact Persons:
The nurse researcher involved with the study is available to answer any questions you 
may have about this study. The study advisor may also be able to answer your questions. 
If you have questions, concerns or complaints, you may contact Phyllis Boone at the 
address above or the study advisor. Dr. Cynthia Coviak at the same address. The contact 
information below may be used if you have any questions, eoncems or complaints about
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the research, or think the research has hurt you. You may use this contact information if  
you want to get information or provide input about this research. You may use this 
contact information if you have questions about your rights as a research volunteer.
• The Spectrum Health Office of the IRB at (616) 486-2031
• The Grand Valley State University Human Rights and Research 
Committee Representative at 616-331-3197
Consent;
By signing this consent form and HIPAA authorization, you certify you have read this 
form, you have had the opportunity to ask questions about this study and this form, and 
you have received answers that fully satisfy those questions. You are voluntarily signing 
this consent form and HIPAA authorization because you have decided to participate in 
this study. You are also giving authorization for release of all of your protected health 
information relative to this research. You understand that you may withdraw your 
consent and HIPAA authorization at any time and your care will not suffer.
You will receive a signed copy of this Research Informed Consent Form and HIPAA 
Authorization.
By signing this consent form, you will not give up any of your legal rights or release the
parties involved in this study from liability for negligence.
Printed Name of Patient:______________________________________
Signature of Patient:_______________________________Date:_________________
I would like a summary of the study results. (Initial) Yes No
Signature of Person Obtaining Consent:
Date:
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Interview Guide
APPENDIX H 
Interview Guide
Interview Guide
Participant #____  Date:_________ Time;
The participant understands the purpose of the study, his or her role, has had an 
opportunity to clarify concerns, and has signed the consent for participation and HIPAA 
release: Yes No______
Can you tell me about what it is like for you to live with IV prostaglandin treatment for 
your pulmonary hypertension? Please share as many of your thoughts, experiences and 
feelings as you can recall.
Can you tell me what your life like before you needed this treatment?
Can you tell me about your life now—have there been changes?
Can you tell me how you feel about being on the IV medicine?
What is this experienee like for you?
Is there anything else about being on this treatment that you would like to share?
Notes:
Does participant have eoncluding questions or eoncems? Yes No_____
The participant has a PAH Clinic Contact sheet. Yes N o _____
The participant is to be thanked for time and participation. Token gift for participation
given: Yes_____
Time concluded:
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APPENDIX I 
Contact Information for the Heart Failure Clinic
(616)486-6550
By dialing the number above, you will be directed by a telephone tree or by the 
administrative assistant to the appropriate agency or person that will be able to help you 
with problems that may arise during or as a result of your participation in the research 
interview.
For life-threatening, emergent conditions you will be directed to call the emergency 
response system at 9-1-1.
Clinic Physicians are; Dr. Wilt and Dr. Berjaoui. They are available on PAH clinic days. 
There are 3 Nurse Practitioners as well as Registered Nurses that may help you.
A Pharmacist is available on Pulmonary Hypertension clinic days.
A Social Worker is available.
Additional Resources 
Airway Oxygen Inc. (616) 247-3900 or toll free (800) 632-0730 
Carelinc Medical Equipment and Supply (616) 776-3602 
Wright & Filippis Medical Equipment and Supply (616) 531-1340
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a p p e n d i x ;
IRB and HRRC Research Approval Letters 
IRB Approval of Research at Spectrum Health July 26, 2010
Institutional Review Board
100 Michigan NE, MC 038
Grand Rapids, MI 49503
616.391.3050
irb@spectrum-health. or g
WWW, spectrum-health. ore/research
APPROVAL OF RESEARCH
July 26, 2010
Phyllis Boone RN BSN
Kirkhof College of Nursing at GVSU
807 Cooks Crossing Dr. SE
Byron Center, MI 49315
TYPE OF REVIEW: Initial, Non-Committee Review
IRB#: 2010-109 (please reference this number in all correspondence with the IRB) 
PROTOCOL NAME: The lived experience: Pulmonary arterial hypertension and 
intravenous 
prostaglandin therapy
Dear Ms. Boone:
The above referenced protocol and associated materials were reviewed and approved by 
the IRB via
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expedited review on July 21, 2010 under Categories 5, 6,and 7 as described in 45 CFR 
46.110.
The approval period for this research is from July 21, 2010 to July 20, 2011.
The IRB reviewed the following documents related to the approval of the research 
proposal:
□ Study protocol dated 7/12/2010
□ Informed Consent Form dated 7/12/2010
□ Data collection form dated 7/12/2010
□ Recruitment postcard dated 7/12/2010
□ Recruitment letters dated 7/12/2010
□ Study Application dated 07/14/2010
□ PAH clinic contact sheet dated 7/12/2010
□ Interview guide dated 7/12/2010
Any changes made to the study following this approval, including informed consent 
changes, require
submission in writing to the IRB and approval by the committee. Changes may not be 
implemented until
approved by the IRB except when necessary to eliminate apparent immediate hazards to 
the subject.
Approval of your research means you are responsible for complying with all applicable 
policies and
procedures of the FDA, CHRP, HIPAA, Spectrum Health, and the Spectrum Health IRB. 
Also, please be
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advised that unanticipated problems involving risk to subjects or others must be promptly 
reported to the
IRB. You may reference the Investigator Manual for guidance on expectations of the IRB 
after approval.
The IRB requires submission of the “FORM; Continuing Review Progress Report or 
Study Completion
Report” to the committee prior to the study expiration date. It is recommended you 
submit this form 4-6
weeks prior to the expiration date to allow time for processing. Your study approval 
expires on July 20,
2011 at 11:59pm and cannot continue until re-approved by the Spectrum Health IRB. If 
your study has
been completed, terminated, or if you do not wish to continue, please submit the study 
completion portion
of the aforementioned form before the expiration date.
If you have any questions please contact the Spectrum Health IRB office at 616-486- 
2031, email
irbassist@spectrum-health.org, or visit us on the web at www. spectrum- 
health. or g/research.
Sincerely,
Jeffrey Jones MD
Chair, Spectrum Health IRB
cc: Dr. Cynthia Coviak, PhD, RN
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IRB Approval of Research at Spectrum Health November 8, 2010
Institutional Review Board
100 Michigan NE, MC 038
Grand Rapids, MI 49503
616.391.3050
irb@spectrum-health.org
WWW. spectrum-health. org/research
APPROVAL OF RESEARCH
November 8, 2010
Phyllis Boone RN BSN
Kirkhof College of Nursing at GVSU
807 Cooks Crossing Dr. SE
Byron Center, MI 49315
TYPE OF REVIEW: Modifications, Non-Committee Review
IRB#: 2010-109 (please reference this number in all correspondence with the IRB)
PROTOCOL NAME: The lived experience: Pulmonary arterial hypertension and
intravenous
prostaglandin therapy
Dear Ms. Boone:
The request for modification of approved human research and associated materials were 
reviewed and
approved on November 8, 2010.
As a reminder, IRB approval for this research expires on July 20,2011.
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The IRB reviewed the following documents related to the approval of the modification: 
n Modification of Approved Research form signed 11/03/10 
□ Study protocol dated 10/30/2010
If you have any questions please contact the Spectrum Health IRB office at 616-486- 
2031, email
irbassist@spectrum-health.org, or visit us on the web at www. spectrum- 
health. or g/ research.
Sincerely,
Jeffrey Jones MD 
Chair, Spectrum Health IRB
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IRB Study Completion at Spectrum Health, January 31, 2011 
Page 1 of 1 HRP-516 
Institutional Review Board 
100 Michigan NE, MC 038 
Grand Rapids, Ml 49503
616.391.3050 
irb@spectrum-health. org 
WWW. spectrum-health. org/research 
STUDY COMPLETION 
January 31,2011 
Phyllis Boone RN BSN 
Kirkhof College of Nursing at GVSU 
807 Cooks Crossing Dr. SE 
Byron Center, Ml 49315 
IRB#: 2010-109
PROTOCOL TITLE: The lived experience: Pulmonary arterial hypertension and
intravenous
prostaglandin therapy
Dear Phyllis,
On January 31,2011 the IRB reviewed and has acknowledged your request for closure of 
the human
subject research for the above referenced protocol.
As part of this action:
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□ The research is permanently closed to enrollment.
□ All subjects have completed all research-related interventions.
□ Collection of private identifiable information is completed.
□ Analysis of private identifiable information is completed.
Should you have any questions please contact the Spectrum Health IRB office at 616- 
486-2031.
Sincerely,
Jeffrey Jones MD
Chair, Spectrum Health IRB
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HRRC Approval of Research, GVSU August 11, 2010
Please note that Grand Valley State University Human Research Review Committee has 
taken the following action on IRBNet:
Project Title: [142412-2] The lived experience: Pulmonary arterial hypertension and
intravenous prostaglandin therapy
Principal Investigator: Phyllis Boone, MSN Student
Submission Type: Amendment/Modification 
Date Submitted: July 29, 2010
Action: APPROVED 
Effective Date: August 11, 2010 
Review Type: Expedited Review
Should you have any questions you may contact Christina Moord at moordc@gvsu.edu. 
Thank you.
The IRBNet Support Team 
www.irbnet.org
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HRRC Change in Protocol Approval, GVSU November 10, 2010
Please note that Grand Valley State University Human Research Review Committee has 
published the following Board Document on IRBNet:
Project Title: [142412-3] The lived experience: Pulmonary arterial hypertension and
intravenous prostaglandin therapy
Principal Investigator: Phyllis Boone, MSN Student
Submission Type: Amendment/Modification 
Date Submitted: November 10, 2010
Document Type: Change in Protocol Approval Letter 
Document Description: Change in Protocol Approval Letter 
Publish Date: November 16, 2010
Should you have any questions you may contact Paul Reitemeier at reitemep@,evsu. edu. 
Thank you.
The IRBNet Support Team
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APPENDIX K
The Inservice Protocol for the Nursing Staff, Spectrum Health Heart Failure, Transplant and
Pulmonary Hypertension Clinic
APPENDIX K
The Inservice Protocol for the Nursing Staff, Spectrum Health Heart Failure, Transplant
and Pulmonary Hypertension Clinic 
The Lived Experience: Pulmonary Arterial Hypertension and Intravenous
Prostaglandin Therapy
1) Objectives
a) A descriptive phenomenological study that will
i) Obtain a subjective description of the experience of living with intravenous 
prostaglandin therapy for Pulmonary Arterial Hypertension (PAH)
ii) Determine what kinds of elements are common to the experience with study 
participants
iii) Develop an aggregate structure of the experience from the individual 
descriptions of it
iv) Add to what is now known about the phenomenon
b) To determine how nurses can help future patients to live optimally within the
confines of a palliative treatment for this incurable illness.
2) Study Related Functions for the Nursing Staff
a) A possible research opportunity for your patient
i) Double blinded to protect the identity and participation of clinic patients to 
meet HIPAA requirements
ii) Identify patients among the clinic population that are receiving intravenous 
prostaglandin therapy for PAH.
iii) Distribute the study introductory letter to clients identified as receiving 
intravenous prostaglandin therapy for the study.
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(1) The clients will respond by returning the letter to the primary investigator 
in a stamped envelope self-addressed to the primary investigator.
(2) The identity of clients receiving the introductory letter is to remain 
confidential
(a) The researcher will only know about clients who choose to respond to 
the recruitment letter.
(b) Clinic staff will only know the identities of clients to whom they have 
distributed the recruitment letter.
(3) Maintain a list of clients receiving the introductory letter using the log 
form provided. The log will be used solely for the purpose of sending 
reminder cards.
iv) Postcard reminder to clinic patients for the purpose of stimulating recruitment. 
The stamped postcards will provided by the primary researcher.
(a) All clinic clients that were given a recruitment letter will be sent a 
postcard reminder by clinic staff one week after the letters are 
distributed.
(b) The card will have the following message:
(i) This is a reminder to you about the study of what it is like for you 
to take intravenous medicine for your PAH.
(ii) If you have not done so already and would like to be part of this 
study by sharing your story, please fill out and return the letter in 
the envelope that you were given at the PAH clinic.
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(iii)If you have any questions about the study, you can contact the 
primary researcher at the e-mail address or the phone number that 
is given in the letter you received at the clinic. She will be happy to 
help you.
(iv) Whether you have already returned the letter or decided that you 
cannot participate, we’d like to thank you for considering being a 
participant in this study.
b) Direct any questions or concerns you may have about your role to the primary 
researcher.
i) Contact information for the primary researcher;
Phyllis D. Boone BSN, RN, MSN student
Kirkhof College of Nursing at Grand Valley State University
boonep@mail. gvsu. edu
ii) Contact information for the faculty advisor:
Dr. Cynthia Coviack, PhD, RN, CNE
Kirkhof College of Nursing at Grand Valley State University
coviakc@,gvsu. edu
iii) Contact information for the on-site coordinator:
Kristina Simmons, LMSW
Spectrum Health Heart Failure, Transplant and PAH Clinic 
kristina. simmons@spectrum-health, org
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APPENDIX L 
Research Certifications for Phyllis D. Boone
APPENDIX L 
Research Certifications for Phyllis D. Boone 
National Institutes of Health Certificate for completion of Human Research Course
Certificate of Completion
The National Institutes of Health (NIH) Office of Extramural Research certifies that 
Phyllis Boone successfully completed the NIH Web-based training course “Protecting 
Human Research Participants”.
Date of completion: 10/26/2009
Certification Number: 327845
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CITI Human Research Course Record of Completions for GVSU
CITI Collaborative Institutional Training Initiative
Human Research Curriculum Completion Report 
Printed on 1/8/2011 
Learner: Phyllis Boone (username; boonep)
Institution: Grand Valley State University 
Contact Information 807 Cooks Crossing Drive SE
Byron Center, MI 49315 USA 
Department: Nursing 
Phone: 616-204-2481 
Email: boonepd_l@comcast.net 
Group 1 Biomedical Research Investigators and Key Personnel: Biomedical Research 
Investigators and Key Personnel. To meet the basic GVSU requirements, complete all 9 
"required" modules plus any 3 "optional" Modules. Be sure to complete all associated 
quizzes.
Stage 2. Refresher Course Passed on 10/15/09 (Ref # 3645859)_________
Required Modules
Refresher Course 200 Introduction 
History and Ethical Principles. 
Regulations and Process, Part 1 
Regulations and Process, Part 2 
llnformed Consent.
Social & Behavioral Research (SBR) 
Genetics Research, Part 1 
Genetics Research, Part 2 
Records-Based Research, Part 1 
Records-Based Research, Part 2
Date
Complete
d
I 10/15/09 I no quiz 
j 10/15/09 ! no quiz
Î 10/15/09 :T/T(f00%)
! '
I i b / ï v o 9 l i / î  (100%) 
i ib /îs m  ' ji7i"
j  10/15/09" Î2/2 (Tob%) 
i 10/15/09 11/1 (100%)
; 10/1^9"^! ur(îbô% ) 
rm7Î5769":i7r(ibô%  
rïo7Ï5/Ô9 'm(i(^%^^
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Records-Based Research, Part 3 . 10/15/09 l/I (100%)
Research with Protected Populations - Vulnerable Subjects: A 
Definition.
1 10/15/09 'i7r(io6%)
[Vulnerable Subjects - Prisoners, Part I ! Io7l5/09 l î /X Ï o ô ^
Vulnerable Subjects - Prisoners, Part 2 r 10/15/09
1
T/ÏTlÔ6 %)
Studies With Minors, Part 1 rTo7iÿo9 i i / ï ( i o 6 %)
Studies With Minors, Part 2 ; 10/15/09 ll/I  (100%)
:Studies With Minors, Part 3 ri6/i57o9 !i7r(T66%)
Studies with Pregnant Women and Fetuses, Part 1 riÔ/Ï5/09^ I/I (100%)
Studies with Pregnant Women and Fetuses, Part 2 1 10/15769 i7 r ( io 6 ^
[Group Harms; Research with Culturally or Medically 
Vulnerable Groups,
j" i67Î5769 :'3/3(l66%)
HIPAA and Human Subjects Research. ; 10/15/09 2/2(100%)
Conflicts of Interest in Research Involving Human Subjects. riO/15709 i2 /2 ( ï 6 o%)
How to Complete the CITI Refresher Course and Receive a 
Completion Report
r 10/15/69 no quiz
For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
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CITI Human Research Curriculum Completion Reports for Spectrum Health
CITI Collaborative Institutional Training Initiative
Human Research Curriculum Completion Report 
Printed on 1/8/2011 
Learner: Phyllis Boone (username; boonep)
Institution: Spectrum Health 
Contact Information 100 Michigan NE
Grand Rapids, MI 49501 USA 
Phone; 616-391-3050 
Email; boonepd_l@comcast.net 
Biomedical Research: Choose this group to satisfy CITI training requirements for 
Investigators and staff involved primarily in biomedical research with human subjects.
Stage 1. Basic Course Passed on 10/15/09 (Ref # 3645947)
Required Modules
Date
Completed Score
Belmont Report and CITI Course Introduction : 10/15/09 3/3(100%)
History and Ethical Principles r 11/02/06 15/5(166%)
Basic Institutional Review Board (IRB) Regulations and 
Review Process-
1 11/02/06 ;5/5(i66%)
Informed Consent i 11/0^06 :4/4(ïo6%)
{Social and Behavioral Research for Biomedical Researchers : 11/02/06 ;^ (lo6% )
Records-Based Research 11/02/06 j2/2 (100%)
Genetic Research in Human Populations 1 11/03/06^ |2/2(l66%)
{Research With Protected Populations -  Vulnerable Subjects; 
An Overview
riï/D3/Ô6' |4M7î66%)
Vulnerable Subjects -  Research Involving Minors T Ïb/Î5/Ô^ :3/3l(lÔ6%)
|FDA-Regulated Research rib7ïÿo9 ;575 ( i6 6 ^
Research and HIPAA Privacy Protections j lî/c ü jb ô ' !^2(Î66%)
Hot Topics i 10/15/09 no quiz
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Conflicts of Interest in Research Involving Human Subjects i  11/03/06 2/2 ( 100%)
Spectrum Health ■ 10/15/09 ' no quiz
For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
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CITI Health Information Privacy and Security Curriculum Completion Report for
Spectrum Health
CITI Collaborative Institutional Training Initiative
CITI Health Information Privacy and Security (HIPS) Curriculum Completion
Report
Printed on 1/8/2011
Learner: Phyllis Boone (username; boonep)
Institution: Spectrum Health
Contact Information 100 Michigan NE
Grand Rapids, MI 49501 USA 
Phone: 616-391-3050 
Email: boonepd_l@comcast.net
Health Information Privacy and Security (HIPS):
Stage 1. Basic Course Passed on 10/19/09 (Ref# 3645950)
Elective Modules
Date
Completed Score
About the Course ! l6/19/09 : T/Ï (100%)
jPrivacy Rules: Introduction to Federal and State 
Requirements*
..... i'To/i^o^ rÿ i6 (% % )
Privacy Rules: Clinicians* i 10/19/09 : 8/8lïïÔ0%^
jPrivacy Rules and Research* " rîb7Ï9/Ô9'' id/io(ib6%)
Privacy Rules: Students and Instructors* ; 1Ô/Ï9/Ô9 ^ /^ ib io ^ '"
Privacy Rules: Fundraisers* j 10/19/09 "5/5(iôô% r
privacy Rules: Marketers* r  10/19/09 575(100^
jSecurity Rules: Basics of Being Secure, Part 1* 1 ïo7ïÿÔ9 ' no quiz
Security Rules: Basics of Being Secure, Part 2* iô7iô(ibb%)
Security Rules: Protecting your Computer* ; 10/19/09 7/8 (88%)
1 0 0
Security Rules; Picking and Protecting Passwords** ; 10/19/09: { 8/8(100%)
{Security Rules: Protecting your Portables* '  ' fÔ/Ï9/Ô9
Security Rules: Protecting your identity*
i
: 10/19/09
i
! 7/7(100%)
Security Rules: Safer Email-ing and IM-ing, Part 1* ' rfo/Ï9/b9 i no quiz
{Security Rules: Safer Email-ing and IM-ing, Part 2* " ^ rib /îw b ^ rï57i^ 94% r
'Security Rules: Safer Web Surfing* ! Ïb7i9/b9 8/8 (ibb% )'
Security Rules: Introduction to HIPPA Security 
{Requirements*
{ ïb/îb/bg
i
; 4/6 (67%) "
Security Rules: Issues for Work/Workers OffiSite* r 10/19/09 4A4(10094)
Completing the Privacy and Security Course : îo/ib/bb ; no quiz
For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
Re
1 0 1
CITI Responsible Conduct of Research Curriculum Report for Spectrum Health
CITI Collaborative Institutional Training Initiative (CITI)
Responsible Conduct of Research Curriculum Completion Report
Printed on 1/8/2011
Learner: Phyllis Boone (username: boonep)
Institution: Spectrum Health
Contact Information 100 Michigan NE
Grand Rapids, MI 49501 USA 
Phone: 616-391-3050 
Email: boonepd_l@comcast.net
Social and Behavioral Responsible Conduct of Research Course 1.:
Stage 1. Basic Course Passed on 10/20/09 (Ref # 3645949)
Required Modules
' Date 
Completed { Score
The CITI Course in the Responsible Conduct of Research 1 10/15/09 ; no quiz
Introduction to the Responsible Conduct of Research i'To/is/og'' ; no quiz
Introduction to Research Misconduct 1 10/16/09 1 no quiz
Research Misconduct 2-1495 Ï 1 0 /2 0 /0 9 ""|576(83%r
{Case Study - In the Field, No One Will Know 2-121s rïo/20/09 |3/3 (100%)
Introduction to Data Acquisition and Management
1 '  { 16 /2 0 )^ 9 I no quiz
{Data Acquisition, Management, Sharing and Ownership 215
_ _ _ _ _ _ _ _ _ _ _ _
15/5^100^
{Case Study - Data Management "The New Clinical Data 
{Manager" BioMed 12-1201
j-—— — -
{ no quiz
Introduction to Responsible Authorship ! 10/16/09 no quiz
jPublication Practices and Responsible Authorship 21 sis rYo/20/09""'575(100?^
Responsible Authorship -Taking Shortcuts (All Science) : 10/20/09 5/5 (100%)
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Responsible Authorship -The Deceased Author (All Science) 10/20/09 4/4 (100%)
Case Study in Irresponsible Authorship Sherry's Secret (All 
Science)
10/20/09 1/1 (100%)
Introduction to Peer Review 10/18/09 no quiz
Peer Review ; ’ 10/20/09 5/5 (100%)
Peer Review and Controversial Research 10/20/09 2/2 (100%)
Introduction to Mentoring 10/18/09 no quiz
Mentoring Case Study: 0 , What a Tangled Web We Weave. 10/18/09 3/4(7594)
Mentoring Case Study: The Graduate Student Laborer. 10/18/09 4/4 (100%)
Mentoring Case Study: Sherry's Secret. 10/18/09 4/4 (100%)
Mentoring Case Study: Lisa Bach's Case 10/18/09 3/3 (100%)
Mentoring Case Study: The Business of Mentoring. 10/18/09 4/4 (100%)
Mentoring Case Study: Too Much Help is Just Too Much! 10/18/09 3/3 (100%)
Introduction to Conflicts o f Interest and Commitment 10/18/09 no quiz
Conflicts of Interest and Commitment 10/20/09 5/6(8394)
Col Case Study -The Case of the Entrepreneurial Psychologist 10/20/09 3/3 (100%)
Introduction to Collaborative Relationships 10/18/09 no quiz
Collaborative Research : - ^ 10/20/09 6/6 (100%)
Marriage Has it's Advantages ) • 10/20/09 2/2 (100%)
The Price of Collaboration 10/18/09 no quiz
A Possible Co-Author 10/18/09 no quiz
Supporting Documentation 10/18/09 no quiz
Facilitating Sharing Between Collaborators 10/18/09 no quiz
The CITI RCR Course Completion Page. 10/18/09 no quiz
Spectrum Health 10/15/09 no quiz
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For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
Return
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APPENDIX M 
Research Certifications for Cynthia Coviak PhD, RN, CNE
APPENDIX M 
Research Certifications for Dr. Cynthia Coviak
CITI Collaborative Institutional Training Initiative
Human Research Currieulum Completion Report 
Printed on 5/14/2010
Learner: Cynthia Coviak (username; ccoviak)
Institution: Grand Valley State University
Contact Information 301 Michigan Street, NE
Cook-DeVos Center for Health Sciences 
Suite 330
Grand Rapids, Michigan 49305 USA 
Department: Nursing 
Phone: 616-331-7170 
Email: coviakc@gvsu.edu
Group 1 Biomedical Research Investigators and Key Personnel: Biomedical Research 
Investigators and Key Personnel. To meet the basic GVSU requirements, complete all 9 
"required" modules plus any 3 "optional" Modules. Be sure to complete all associated 
quizzes.
Stage 1. Basic Course Passed on 01/03/10 (Ref # 695893)
Required Modules
History and Ethical Principles 
Introduction
Basic Institutional Review Board (IRB) Regulations and 
iReview Process
Informed Consent
Social and Behavioral Research for Biomedical Researchers 
Records-Based Research
Date
Complete
d
12/31/09 I 6/7 (86%)
12/31/09 ; no quiz 
T273Ï/09";5/5(lÔ0^
12/31/09 |4/4 ^ 6 % )  
o i / O l / l O  i 3 /4 ( 7 5 '% 0  
0W3/Î0 ^^/2(l6b%)
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Genetic Research in Human Populations 01/03/10 !2/2 (100%)
Research With Protected Populations - Vulnerable Subjects; An 
Overview
6i7o37io |474(Ï6Ô%)
f
Group Harms: Research With Culturally or Medically 
Vulnerable Groups
lo îm /îô " |373[l00%)
Conflicts of Interest in Research Involving Human Subjects ÔÏ7Ô3/Ï0' i272irÔ0%)
Grand Valley State University 01/03/10 , no quiz
For this Completion Report to be valid, the learner listed above must be affiliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
Return
106
CITI Collaborative Institutional Training Initiative
Human Research Curriculum Completion Report 
Printed on 5/14/2010
Learner: Cynthia Coviak (username: ccoviak)
Institution: Spectrum Health
Contact Information Phone: 616-331-7170
Email: coviakc@gvsu.edu
Social/Behavioral Research Course: Choose this group to satisfy CITI training 
requirements for Investigators and staff involved primarily in biomedical research with 
human subjects.
Stage 1. Basic Course Passed on 05/14/10 (Ref # 3952529)
Required Modules
Date
Completed Score
jBelmont Report and CITI Course Introduction : 05/09/10 i3/3(T66%)
Students in Research - SBR 05/09/16 :87io(86%)
History and Ethical Principles - SBR 1 6 5 /6 9 7 1 6 ;4/4(l669^
;Defïning Research with Human Subjects - SBR |l)57697i6" 1^ ( 1 6 6 %)
The Regulations and The Social and Behavioral Sciences - SBR " 6 5 7 6 9 / 1 6" 5 ^ 5 (1 6 6 ^
Assessing Risk in Social and Behavioral Sciences - SBR ; 0 5 /6 9 /1 6 !5/r(i66%)
Informed Consent - SBR 7 6 5 /6 9 7 1 0 :5/5(l66%)
privacy and Confidentiality - SBR 71)57o97i6" 6 7 ^ ^ 6 6 ^
{Research with Children - SBR 6 5 7 6 9 / 1 6 ^[2/4(^% y
{Research in Public Elementary and Secondary Schools - SBR
1
65/147Î6' {4/4(ï66yÿ
{Internet Research - SBR
i
6 5 / 1 4 /1 0 |4/4({l66%)
jHIPAA and Human Subjects Research 05/14/10 12/2 ( 1 6 6 %)
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Conflicts oflnterest in Research Involving Human Subjects 01/03/10 2/2(100%) 
{Spectrum Health ! 05/14/10 i  no quiz
For this Completion Report to be valid, the learner listed above must be affîliated 
with a CITI participating institution. Falsified information and unauthorized use of 
the CITI course site is unethical, and may be considered scientific misconduct by 
your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami 
Director Office of Research Education 
CITI Course Coordinator
Return
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APPENDIX N 
Research Certifications for Kristina Simmons, LMSW
APPENDIX N
CITI Human Research Curriculum Completion Report, Spectrum Health for Kristina
Simmons, LMSW
Omplelion Report
c m  Collaborative Instihitional Training Initiative
Human Research Cuiriculum Completion Report 
Printed on 1/19«D10
Learner: Kristina Simmoiis (username; simmkj)
Institution: Spectrum Health 
Contact 2902 Bradford St ME
Information Grand Rapids, Ml 49505 USA
Department; Care Management 
Phone: €16-468-6990
Email : kristina.ajmmons@speclrum-health.org 
Biomedical Research:
jRegulred Modules
Date
Completed Score
Belmont Report and CiTl Course Introduction 12(26W9 3/3 (100%)
History and Ethical Principles 12(26109 6(7 (66%)
Basic tnstitutionai Review Board (IRB) Regulations and 
Review/ Process
01(16(10 5/5 (100%)
Informed Consent 01(16/10 4/4(100%)
Social and Behavioral Research for Biomedical 
Researchers
01(16/10 3/4 (75%)
Records-Based Research 01/16/10 2/2(100%)
Genetic Research in Human Populations 01/16/10 2/2(100%)
Research W lh Protected Populations - Vulnerable 1  
Subjects: An Overview |
01/17/10 4/4(100%)
Vulnerable Subjects - Research Involving Minors I 01(17/10 3/3(100%)
Ë6Â Regulated Research | 01(17/10 4/5 (60%)
HiPAA and Human Subjects Research | 01/17/10 2/2(100%)
Hot Topics 1 01/17/10 no quiz
Conflicts of Interest in Research Involving Human I 
Subjects 1
01/17/10 2/2(100%)
Spectrum Health 1 01(17/10 no quiz
For this Completion Report to be valid, the learner listed above must be 
affiliated with a CITI participating fnatitudon. Falsified information and 
unauthorized use of the CiTl course site is unethical, and may be 
coneidersd aclentific misconduct by your institution,
Paul Braunschweiger Ph.D.
Professor, Uni'/ersity o f ikfltami 
Director Oft ice o f  R esea rch  Education 
CITI C ourse  Coordinator
Page 1 of 1
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APPENDIX O 
Permission to use Copyrighted Material
APPENDIX O 
Permission to use Copyrighted Material
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